ClinicalTrials.gg
CompletedNCT05827926Updated Dec 23, 2025Results posted

A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults

A Phase 1/2 interventional study of Influenza Vaccine 1 and mRNA-1083.1 in SARS-CoV-2 and Influenza, sponsored by ModernaTX, Inc.. Completed at 69 sites in United States. Open to participants aged 18 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-23.

Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 1/2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
1,758
Allocation
Randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Influenza, Human by Moderna, Inc. — 2 open to participants now, 3 under way, 1 of them phase 3. Influenza, Human · Moderna, Inc..

Enrollment
8th of 23
1,758 · median 885
Started
2023
with 5 others
Phase 1/2
6 of 23
none open now
Registered
13th of 23
by date

Among the 23 studies in Influenza, Human by Moderna, Inc., this one is the 8th largest by enrollment, is one of 6 that started in 2023, is one of 6 in phase 1/2, and was the 13th registered.

Influenza, Human

2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

2 of the 23 studies in Influenza, Human by Moderna, Inc. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Influenza, Human by Moderna, Inc., or all of them as a file.
02

Study summary

The study is divided into 2 parts: Part 1 and Part 2. The purpose of Part 1 of this study is to generate sufficient safety, reactogenicity, and immunogenicity data to enable selection of an mRNA-1083 vaccine composition and dose level to evaluate in a subsequent Phase 3 clinical trial in adults.

The purpose of Part 2 of this study is to generate safety and immunogenicity data for additional mRNA-1083 compositions and dose levels in young adults ≥18 years and \<50 years of age.

Read the detailed description

Part 1: Participants will be enrolled into 1 of 2 age cohorts: Cohort A for adults ≥65 to \<80 years of age or Cohort B for adults ≥18 to \<65 year of age. In Cohort A, approximately 600 participants will be randomized (in equal allocation ratio) into the investigational treatment arms, stratified by influenza vaccine status in the most recent influenza season (received or not received since September 2022). In Cohort B, approximately 624 participants will be randomized (in equal allocation ratio) into the investigational treatment arms, stratified by 2 age groups: ≥18 to \<50 years and ≥50 to \<65 years of age and by influenza vaccine status in the most recent influenza season (received or not received since September 2022).

Part 2: Approximately, 520 participants between ≥18 to \<50 years of age will be randomized (in equal allocation ratio) into the investigational treatment arms, stratified by influenza vaccine status in the most recent influenza season (received or not received since Sept 2023).

03

Conditions studied

  • SARS-CoV-2
  • Influenza

Keywords

  • mRNA-1083
  • mRNA-1083 Vaccine
  • SARS-CoV-2
  • SARS-CoV-2 Vaccine
  • Coronavirus
  • Virus Diseases
  • Messenger RNA
  • Influenza Vaccine
  • Moderna
  • Influenza
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

Part 1 (Phase 1/2)

  • Adults ≥18 to \<80 years of age at the time of consent.
  • (BMI) of 18 kilograms (kg)/square meter (m\^2) to 35 kg/m\^2 (inclusive) at the Screening Visit.
  • Healthy as determined by medical evaluation, including medical history, physical examination, and laboratory tests.
  • For female participants of : negative pregnancy test, adequate or has abstained from all activities that could result in pregnancy for at least 28 days prior to Day 1, agreement to continue adequate contraception through 90 days following vaccine administration, and not currently breastfeeding.
  • Fully vaccinated for COVID-19 primary series according to the locally authorized or approved regimen, and their last COVID-19 vaccine (primary series or booster) was ≥120 days prior to Day 1.

Part 2 (Phase 2 Extension)

  • Adults ≥18 to \<50 years of age at the time of consent.
  • BMI of 18 kg/m\^2 to 35 kg/m\^2 (inclusive) at the Screening Visit.
  • Healthy as determined by medical evaluation, including medical history, and physical examination.
  • For female participants of childbearing potential: negative pregnancy test, adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to Day 1, agreement to continue adequate contraception through 90 days following vaccine administration, and not currently breastfeeding.
  • Have received at least 2 doses of locally authorized or approved COVID-19 vaccines and last dose was ≥90 days prior to Day 1.

Key Exclusion Criteria:

Part 1 (Phase 1/2) and Part 2 (Phase 2 Extension)

  • Participant is acutely ill or febrile (temperature ≥38.0 degrees Celsius [°C]/100.4 degrees Fahrenheit [°F]) 72 hours prior to or at the Screening Visit or Day 1.
  • Any medical, psychiatric, or occupational condition, including reported history of drug or alcohol abuse, that, in the opinion of the Investigator, might pose additional risk due to participation in the clinical trial or could interfere with the interpretation of study results.
  • Participant has received systemic for >14 days in total within 180 days prior to Screening Visit (for ≥10 milligrams [mg]/day of prednisone or equivalent) or is anticipating the need for systemic immunosuppressive treatment at any time during participation in the clinical trial (including intra-articular steroid injections). Inhaled, nasal, and topical steroids are allowed.
  • Participant has received or plans to receive any vaccine authorized or approved by a local health agency ≤28 days prior to study intervention administration or plans to receive a vaccine authorized or approved by a local health agency within 28 days after study intervention administration.
  • Participant has received a seasonal influenza vaccine or any other influenza vaccine within 150 days prior to Day 1.
  • Participant tested positive for influenza by local health authority-approved testing methods ≤150 days prior to Day 1.
  • Participant has had close contact to someone with COVID-19 as defined by the Centers for Disease Control and Prevention (CDC) in the past 10 days prior to Day 1.
  • Participant has donated ≥450 milliliters (mL) of blood products within 28 days prior to the Screening Visit or plans to donate blood products during the clinical trial.
  • Working or has worked as study personnel, is an immediate family member or household member of study personnel, study site staff, or Sponsor personnel, or resides in a nursing home.

Part 2 (Phase 2 Extension) Only

  • Participants who enrolled in Part 1 of the mRNA-1083-P101 (Phase 1/2) study.

Note: Other inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
1,758 participants (actual)

Study arms

  • Experimental
    Part 1 Cohort A2: mRNA-1083.1 Dose B

    Participants will receive single intramuscular (IM) injection of mRNA-1083.1 at Dose Level B on Day 1.

    Biological: mRNA-1083.1

  • Experimental
    Part 1 Cohort A3: mRNA-1083.1 Dose C

    Participants will receive single IM injection of mRNA-1083.1 at Dose Level C on Day 1.

    Biological: mRNA-1083.1

  • Experimental
    Part 1 Cohort A4: mRNA-1083.2 Dose A

    Participants will receive single IM injection of mRNA-1083.2 at Dose Level A on Day 1.

    Biological: mRNA-1083.2

  • Experimental
    Part 1 Cohort A5: mRNA-1083.2 Dose B

    Participants will receive single IM injection of mRNA-1083.2 at Dose Level B on Day 1.

    Biological: mRNA-1083.2

  • Experimental
    Part 1 Cohort A6: mRNA-1083.2 Dose C

    Participants will receive single IM injection of mRNA-1083.2 at Dose Level C on Day 1.

    Biological: mRNA-1083.2

  • Experimental
    Part 1 Cohort A7: mRNA-1083.3

    Participants will receive single IM injection of mRNA-1083.3 on Day 1.

    Biological: mRNA-1083.3

  • Active comparator
    Part 1 Cohort A8: Investigational Influenza Vaccine 1

    Participants will receive single IM injection of Investigational Influenza Vaccine 1 on Day 1.

    Biological: Investigational Influenza Vaccine 1

  • Active comparator
    Part 1 Cohort A9: Investigational COVID-19 Vaccine 1

    Participants will receive single IM injection of Investigational COVID-19 Vaccine 1 on Day 1.

    Biological: Investigational COVID-19 Vaccine 1

  • Active comparator
    Part 1 Cohort A10: COVID-19 Vaccine 1

    Participants will receive single IM injection of COVID-19 Vaccine 1 on Day 1.

    Biological: COVID-19 Vaccine 1

  • Active comparator
    Part 1 Cohort A11: Investigational Influenza Vaccine 2

    Participants will receive single IM injection of Investigational Influenza Vaccine 2 on Day 1.

    Biological: Investigational Influenza Vaccine 2

  • Active comparator
    Part 1 Cohort A12: Influenza Vaccine 1

    Participants will receive single IM injection of Influenza Vaccine 1 on Day 1.

    Biological: Influenza Vaccine 1

  • Active comparator
    Part 1 Cohort A13: Influenza Vaccine 2

    Participants will receive single IM injection of Influenza Vaccine 2 on Day 1.

    Biological: Influenza Vaccine 2

  • Experimental
    Part 1 Cohort B1: mRNA-1083.1 Dose A

    Participants will receive single IM injection of mRNA-1083.1 at Dose Level A on Day 1.

    Biological: mRNA-1083.1

  • Experimental
    Part 1 Cohort B2: mRNA-1083.1 Dose B

    Participants will receive single IM injection of mRNA-1083.1 at Dose Level B on Day 1.

    Biological: mRNA-1083.1

  • Experimental
    Part 1 Cohort B3: mRNA-1083.1 Dose C

    Participants will receive single IM injection of mRNA-1083.1 at Dose Level C on Day 1.

    Biological: mRNA-1083.1

  • Experimental
    Part 1 Cohort B4: mRNA-1083.2 Dose A

    Participants will receive single IM injection of mRNA-1083.2 at Dose Level A on Day 1.

    Biological: mRNA-1083.2

  • Experimental
    Part 1 Cohort B5: mRNA-1083.2 Dose B

    Participants will receive single IM injection of mRNA-1083.2 at Dose Level B on Day 1.

    Biological: mRNA-1083.2

  • Experimental
    Part 1 Cohort B6: mRNA-1083.2 Dose C

    Participants will receive single IM injection of mRNA-1083.2 at Dose Level C on Day 1.

    Biological: mRNA-1083.2

  • Experimental
    Part 1 Cohort B7: mRNA-1083.3

    Participants will receive single IM injection of mRNA-1083.3 on Day 1.

    Biological: mRNA-1083.3

  • Active comparator
    Part 1 Cohort B8: Investigational Influenza Vaccine 1

    Participants will receive single IM injection of Investigational Influenza Vaccine 1 on Day 1.

    Biological: Investigational Influenza Vaccine 1

  • Active comparator
    Part 1 Cohort B9: Investigational COVID-19 Vaccine 1

    Participants will receive single IM injection of Investigational COVID-19 Vaccine 1 on Day 1.

    Biological: Investigational COVID-19 Vaccine 1

  • Active comparator
    Part 1 Cohort B10: COVID-19 Vaccine 1

    Participants will receive single IM injection of COVID-19 Vaccine 1 on Day 1.

    Biological: COVID-19 Vaccine 1

  • Active comparator
    Part 1 Cohort B11: Investigational Influenza Vaccine 2

    Participants will receive single IM injection of Investigational Influenza Vaccine 2 on Day 1.

    Biological: Investigational Influenza Vaccine 2

  • Active comparator
    Part 1 Cohort B12: Influenza Vaccine 1

    Participants will receive single IM injection of Influenza Vaccine 1 on Day 1.

    Biological: Influenza Vaccine 1

  • Experimental
    Part 2: mRNA-1083 Composition 1 Dose A

    Participants will receive single IM injection of mRNA-1083 Composition 1 at Dose Level A on Day 1.

    Biological: mRNA-1083

  • Experimental
    Part 2: mRNA-1083 Composition 2 Dose A

    Participants will receive single IM injection of mRNA-1083 Composition 2 at Dose Level A on Day 1.

    Biological: mRNA-1083

  • Experimental
    Part 2: mRNA-1083 Composition 1 Dose B

    Participants will receive single IM injection of mRNA-1083 Composition 1 at Dose Level B on Day 1.

    Biological: mRNA-1083

  • Experimental
    Part 2: mRNA-1083 Composition 2 Dose B

    Participants will receive single IM injection of mRNA-1083 Composition 2 at Dose Level B on Day 1.

    Biological: mRNA-1083

  • Experimental
    Part 2: mRNA-1083 Composition 1 Dose C

    Participants will receive single IM injection of mRNA-1083 Composition 1 at Dose Level C on Day 1.

    Biological: mRNA-1083

  • Experimental
    Part 2: mRNA-1083 Composition 2 Dose C

    Participants will receive single IM injection of mRNA-1083 Composition 2 at Dose Level C on Day 1.

    Biological: mRNA-1083

  • Experimental
    Part 2: mRNA-1083 Composition 1 Dose D

    Participants will receive single IM injection of mRNA-1083 Composition 1 at Dose Level D on Day 1.

    Biological: mRNA-1083

  • Experimental
    Part 2: mRNA-1083 Composition 2 Dose D

    Participants will receive single IM injection of mRNA-1083 Composition 2 at Dose Level D on Day 1.

    Biological: mRNA-1083

  • Active comparator
    Part 2: Investigational Influenza Vaccine 1 Dose A

    Participants will receive single IM injection of Investigational Influenza Vaccine 1 at Dose Level A on Day 1.

    Biological: Investigational Influenza Vaccine 1

  • Active comparator
    Part 2: Investigational Influenza Vaccine 1 Dose B

    Participants will receive single IM injection of Investigational Influenza Vaccine 1 at Dose Level B on Day 1.

    Biological: Investigational Influenza Vaccine 1

  • Active comparator
    Part 2: Investigational COVID-19 Vaccine 2

    Participants will receive single IM injection of Investigational COVID-19 Vaccine 2 on Day 1.

    Biological: Investigational COVID-19 Vaccine 2

  • Active comparator
    Part 2: COVID-19 Vaccine 2

    Participants will receive single IM injection of COVID-19 Vaccine 2 on Day 1.

    Biological: COVID-19 Vaccine 2

  • Active comparator
    Part 2: Influenza Vaccine 1

    Participants will receive single IM injection of Influenza Vaccine 1 on Day 1.

    Biological: Influenza Vaccine 1

Interventions

  • BiologicalInfluenza Vaccine 1

    quadrivalent seasonal influenza vaccine

  • BiologicalmRNA-1083.1

    Sterile liquid for injection

  • BiologicalmRNA-1083.2

    Sterile liquid for injection

  • BiologicalmRNA-1083.3

    Sterile liquid for injection

  • BiologicalInvestigational Influenza Vaccine 1

    Sterile liquid for injection

  • BiologicalInvestigational COVID-19 Vaccine 1

    Sterile liquid for injection

  • BiologicalCOVID-19 Vaccine 1

    Sterile liquid for injection

  • BiologicalInvestigational Influenza Vaccine 2

    Sterile liquid for injection

  • BiologicalInfluenza Vaccine 2

    quadrivalent seasonal influenza vaccine

  • BiologicalmRNA-1083

    Sterile liquid for injection

  • BiologicalInvestigational COVID-19 Vaccine 2

    Sterile liquid for injection

  • BiologicalCOVID-19 Vaccine 2

    Sterile liquid for injection

06

What researchers measure

Primary outcomes

  1. Parts 1 and 2: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)

    Solicited ARs (local and systemic) were reported by participants an electronic diary (eDiary). Local ARs included: injection site pain, injection site erythema (redness), injection site swelling/induration (hardness), and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs included: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills.

    Time frame: Up to 7 days after study injection

  2. Parts 1 and 2: Number of Participants With Unsolicited Adverse Events (AEs) and Severe AEs

    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. Severity for all unsolicited AEs was determined by the Investigator based upon medical judgment and graded as Mild, Moderate or Severe. Number of participants with unsolicited AEs (SAEs and non-serious AEs) and severe AEs up to 28 days post-vaccination are reported in this outcome measure. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

    Time frame: Up to 28 days after study injection

  3. Parts 1 and 2: Number of Participants With Unsolicited Medically Attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), Serious Adverse Events (SAEs), and AEs Leading to Study Discontinuation

    An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability/permanent damage, was a congenital anomaly/birth defect, or was an important medical event. AESIs were protocol-defined medical concepts. An MAAE is an AE that lead to an unscheduled visit to an healthcare practitioner. This included visits to a study site for unscheduled assessments (for example, abnormal laboratory follow-up, and/or COVID-19 and visits to healthcare practitioners external to the study site. Number of participants with SAEs, AESIs, MAAEs, and AEs leading to study discontinuation up to Day 181 are reported in this outcome measure. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

    Time frame: Day 1 through Day 181

  4. Part 2: Geometric Mean Titer (GMT) of Antibodies for Influenza at Day 29, as Measured by Hemagglutination Inhibition (HAI) Assay

    Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. Antibody values reported as below the lower limit of quantification (LLOQ) were replaced by 0.5 \* LLOQ. Values greater than the upper limit of quantification (ULOQ) were converted to the ULOQ. LLOQ = 10 and ULOQ = 3620 for Influenza A H1N1 antibody, LLOQ = 10 and ULOQ = 5120 for Influenza A H3N2 antibody, LLOQ = 10 and ULOQ = 1356 for Influenza B/Victoria-lineage antibody, and LLOQ = 10 and ULOQ = 1280 for Influenza B/Yamagata-lineage antibody. 95% confidence interval (CI) was calculated based on the t-distribution of the log-transformed values for geometric mean (GM) titer, then back transformed to the original scale for presentation. Arms based on the applicable vaccine for this Outcome Measure.

    Time frame: Day 29

  5. Part 2: GM Concentration of Antibodies for SARS-CoV-2 at Day 29, as Measured by Pseudovirus Neutralization Assay (PsVNA)

    SARS-CoV-2 strain included Omicron XBB.1.5 antibody. Antibody values reported as below the LLOQ are replaced by 0.5 \* LLOQ. Values greater than the ULOQ are converted to the ULOQ. LLOQ = 38 and ULOQ = 6960 arbitrary units (AU)/milliliter (mL) for SARS-CoV-2 Omicron XBB.1.5 antibody. 95% CI was calculated based on the t-distribution of the log-transformed values for GM concentration, then back transformed to the original scale for presentation. Arms based on the applicable vaccine for this Outcome Measure.

    Time frame: Day 29

  6. Part 2: Geometric Mean Fold-Rise (GMFR) of Antibodies for Influenza at Day 29, as Measured by HAI Assay

    Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were converted to the ULOQ. LLOQ = 10 and ULOQ = 3620 for Influenza A H1N1 antibody, LLOQ = 10 and ULOQ = 5120 for Influenza A H3N2 antibody, LLOQ = 10 and ULOQ = 1356 for Influenza B/Victoria-lineage antibody, and LLOQ = 10 and ULOQ = 1280 for Influenza B/Yamagata-lineage antibody. 95% CI was calculated based on the t-distribution of the log-transformed values for GMFR values, then back transformed to the original scale for presentation. Arms based on the applicable vaccine for this Outcome Measure.

    Time frame: Day 29

  7. Part 2: GMFR of Antibodies for SARS-CoV-2 at Day 29, as Measured by PsVNA

    SARS-CoV-2 strain included Omicron XBB.1.5 antibody. Antibody values reported as below the LLOQ are replaced by 0.5 \* LLOQ. Values greater than the ULOQ are converted to the ULOQ. LLOQ = 38 and ULOQ = 6960 AU/mL for SARS-CoV-2 Omicron XBB.1.5 antibody. 95% CI was calculated based on the t-distribution of the log-transformed values for GMFR values, then back transformed to the original scale for presentation. Arms based on the applicable vaccine for this Outcome Measure.

    Time frame: Day 29

  8. Part 2: Influenza: Percentage of Participants With Seroconversion, as Measured by HAI Assay

    Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. Seroconversion was defined as a pre-vaccination HAI titer \<1:10 and a post-vaccination HAI titer ≥1:40 or a pre-vaccination HAI titer ≥1:10 and a minimum 4-fold rise in post-vaccination HAI antibody titer. Arms based on the applicable vaccine for this Outcome Measure.

    Time frame: Baseline to Day 29

  9. Part 2: SARS-CoV-2: Percentage of Participants With Seroresponse, as Measured by PsVNA

    SARS-CoV-2 strain included Omicron XBB.1.5 antibody. Seroresponse was defined as an increase from below the LLOQ to ≥4 \* LLOQ if Baseline neutralizing antibody (nAb) level was \< LLOQ, or ≥4-fold rise if Baseline nAb level was ≥ LLOQ. LLOQ = 38 and ULOQ = 6960 AU/mL for SARS-CoV-2 Omicron XBB.1.5 antibody. Arms based on the applicable vaccine for this Outcome Measure.

    Time frame: Baseline to Day 29

Secondary outcomes

  1. Part 1: GMT of Antibodies for Influenza, as Measured by HAI Assay

    Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. Antibody values reported as below LLOQ were replaced by 0.5 \* LLOQ. Values greater than ULOQ were converted to ULOQ. LLOQ = 10 and ULOQ = 640 for Influenza A H1N1 and Influenza A H3N2 antibody, LLOQ = 10 and ULOQ = 320 for Influenza B/ Victoria, and LLOQ = 10 and ULOQ = 640 for Influenza B/Yamagata antibody. 95% CI was calculated based on t-distribution of log-transformed values for GM titer, then back transformed to original scale for presentation. PP Set: all randomized participants who received study drug, complied with injection schedule, complied with timings of immunogenicity blood sampling to have a Baseline and at least 1 post-injection assessment at Day 29, had no documented infection of either influenza or SARS-CoV-2 on Day 1 and up to Day 29, had no major dosing error, and had no major protocol deviations or conditions/medications that affected immune response.

    Time frame: Baseline (Day 1), Day 29, and Day 181

  2. Part 1: GMT of Antibodies for SARS-CoV-2, as Measured by PsVNA

    SARS-CoV-2 strain included BA.4/5 and D614G antibody. Antibody values reported as below LLOQ were replaced by 0.5 \* LLOQ. Values greater than ULOQ were converted to ULOQ. LLOQ = 53 and ULOQ = 71376 for SARS-CoV-2 BA.4/5 antibody and LLOQ = 74.1 and ULOQ = 184317 for SARS-CoV-2 D614G antibody. 95% CI was calculated based on t-distribution of log-transformed values for GM titer, then back transformed to original scale for presentation. PP Set: all randomized participants who received study drug, complied with injection schedule, complied with timings of immunogenicity blood sampling to have a Baseline and at least 1 post-injection assessment at Day 29, had no documented infection of either influenza or SARS-CoV-2 on Day 1 and up to Day 29, had no major dosing error, and had no major protocol deviations or conditions/medications that affected immune response.

    Time frame: Baseline (Day 1), Day 29, and Day 181

  3. Part 1: GMFR of Antibodies for Influenza, as Measured by HAI Assay

    Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. Antibody values reported as below LLOQ were replaced by 0.5 \* LLOQ. Values greater than ULOQ were converted to ULOQ. LLOQ = 10 and ULOQ = 640 for Influenza A H1N1 and Influenza A H3N2 antibody, LLOQ = 10 and ULOQ = 320 for Influenza B/Victoria, and LLOQ = 10 and ULOQ = 640 for Influenza B/Yamagata antibody. 95% CI was calculated based on t-distribution of log-transformed values for GMFR, then back transformed to original scale for presentation. PP Set: all randomized participants who received study drug, complied with injection schedule, complied with timings of immunogenicity blood sampling to have a Baseline and at least 1 post-injection assessment at Day 29, had no documented infection of either influenza or SARS-CoV-2 on Day 1 and up to Day 29, had no major dosing error, and had no major protocol deviations or conditions/medications that affected immune response.

    Time frame: Day 29 and Day 181

  4. Part 1: GMFR of Antibodies for SARS-CoV-2, as Measured by PsVNA

    SARS-CoV-2 strain included BA.4/5 and D614G antibody. Antibody values reported as below LLOQ were replaced by 0.5 \* LLOQ. Values greater than ULOQ were converted to ULOQ. LLOQ = 53 and ULOQ = 71376 for SARS-CoV-2 BA.4/5 antibody and LLOQ = 74.1 and ULOQ = 184317 for SARS-CoV-2 D614G antibody. 95% CI was calculated based on t-distribution of log-transformed values for GMFR, then back transformed to original scale for presentation. PP Set: all randomized participants who received study drug, complied with injection schedule, complied with timings of immunogenicity blood sampling to have a Baseline and at least 1 post-injection assessment at Day 29, had no documented infection of either influenza or SARS-CoV-2 on Day 1 and up to Day 29, had no major dosing error, and had no major protocol deviations or conditions/medications that affected immune response.

    Time frame: Day 29 and Day 181

  5. Part 1: Influenza: Percentage of Participants With Seroconversion, as Measured by HAI Assay

    Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. Seroconversion was defined as a pre-vaccination HAI titer \< 1:10 and a post-vaccination HAI titer ≥1:40 or a pre-vaccination HAI titer ≥1:10 and a minimum 4-fold rise in post vaccination HAI antibody titer. PP Set: all randomized participants who received study drug, complied with injection schedule, complied with timings of immunogenicity blood sampling to have a Baseline and at least 1 post-injection assessment at Day 29, had no documented infection of either influenza or SARS-CoV-2 on Day 1 and up to Day 29, had no major dosing error, and had no major protocol deviations or conditions/medications that affected immune response.

    Time frame: Baseline (Day 1) to Day 29, and Day 181

  6. Part 1: SARS-CoV-2: Percentage of Participants With Seroresponse, as Measured by PsVNA

    SARS-CoV-2 strain included BA.4/5 and D614G antibody. Seroresponse was defined as an increase from below the LLOQ to ≥4 x LLOQ if baseline nAb level was \<LLOQ, or ≥4 fold rise if baseline nAb level was ≥LLOQ. PP Set: all randomized participants who received study drug, complied with injection schedule, complied with timings of immunogenicity blood sampling to have a Baseline and at least 1 post-injection assessment at Day 29, had no documented infection of either influenza or SARS-CoV-2 on Day 1 and up to Day 29, had no major dosing error, and had no major protocol deviations or conditions/medications that affected immune response.

    Time frame: Baseline (Day 1) to Day 29, and Day 181

  7. Part 2: GMT of Antibodies for Influenza, as Measured by HAI Assay

    Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were converted to the ULOQ. LLOQ = 10 and ULOQ = 3620 for Influenza A H1N1 antibody, LLOQ = 10 and ULOQ = 5120 for Influenza A H3N2 antibody, LLOQ = 10 and ULOQ = 1356 for Influenza B/Victoria-lineage antibody, and LLOQ = 10 and ULOQ = 1280 for Influenza B/Yamagata-lineage antibody. 95% CI was calculated based on the t-distribution of the log-transformed values for GM titer, then back transformed to the original scale for presentation. Arms based on the applicable vaccine for this Outcome Measure.

    Time frame: Baseline (Day 1), Day 181

  8. Part 2: GM Concentration of Antibodies for SARS-CoV-2, as Measured by PsVNA

    SARS-CoV-2 strain included Omicron XBB.1.5 antibody. Antibody values reported as below the LLOQ are replaced by 0.5 \* LLOQ. Values greater than the ULOQ are converted to the ULOQ. LLOQ = 38 and ULOQ = 6960 arbitrary units (AU)/milliliter (mL) for SARS-CoV-2 Omicron XBB.1.5 antibody. 95% CI was calculated based on the t-distribution of the log-transformed values for GM concentration, then back transformed to the original scale for presentation. Arms based on the applicable vaccine for this Outcome Measure.

    Time frame: Baseline (Day 1), Day 181

  9. Part 2: GMFR of Antibodies for Influenza, as Measured by HAI Assay

    Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. Antibody values reported as below LLOQ replaced by 0.5 \* LLOQ. Values greater than ULOQ converted to ULOQ. LLOQ= 10, ULOQ= 3620 for Influenza A H1N1, LLOQ= 10, ULOQ= 5120 for Influenza A H3N2, LLOQ= 10, ULOQ= 1356 for Influenza B/Victoria-lineage, and LLOQ= 10, ULOQ= 1280 for Influenza B/Yamagata-lineage. 95% CI was calculated based on t-distribution of log-transformed values for GMFR, then back transformed to original scale for presentation. PP Set: all randomized participants who received study drug, complied with injection schedule, complied with timings of immunogenicity blood sampling to have a Baseline and at least 1 post-injection assessment at Day 29, had no documented infection of either influenza or SARS-CoV-2 on Day 1 and up to Day 29, had no major dosing error, and had no major protocol deviations or conditions/medications that affected immune response.

    Time frame: Day 181

  10. Part 2: GMFR of Antibodies for SARS-CoV-2, as Measured by PsVNA

    SARS-CoV-2 strain included Omicron XBB.1.5 antibody. Antibody values reported as below the LLOQ are replaced by 0.5 \* LLOQ. Values greater than the ULOQ are converted to the ULOQ. LLOQ = 38 and ULOQ = 6960 AU/mL for SARS-CoV-2 Omicron XBB.1.5 antibody. 95% CI was calculated based on the t-distribution of the log-transformed values for GMFR values, then back transformed to the original scale for presentation. PP Set: all randomized participants who received study drug, complied with injection schedule, complied with timings of immunogenicity blood sampling to have a Baseline and at least 1 post-injection assessment at Day 29, had no documented infection of either influenza or SARS-CoV-2 on Day 1 and up to Day 29, had no major dosing error, and had no major protocol deviations or conditions/medications that affected immune response.

    Time frame: Day 181

  11. Part 2: Influenza: Percentage of Participants With Seroconversion, as Measured by HAI Assay

    Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. Seroconversion was defined as a pre-vaccination HAI titer \<1:10 and a post-vaccination HAI titer ≥1:40 or a pre-vaccination HAI titer ≥1:10 and a minimum 4-fold rise in post-vaccination HAI antibody titer. PP Set included all randomized participants who received the study intervention, complied with the injection schedule, complied with the timings of immunogenicity blood sampling to have a Baseline and at least 1 post-injection assessment at Day 29, had no documented infection of either influenza or SARS-CoV-2 on Day 1 and up to Day 29, had no major dosing error, and had no major protocol deviations or conditions/medications that affected the immune response.

    Time frame: Baseline (Day 1) to Day 181

  12. Part 2: SARS-CoV-2: Percentage of Participants With Seroresponse, as Measured by PsVNA

    SARS-CoV-2 strain included Omicron XBB.1.5 antibody. Seroresponse was defined as an increase from below the LLOQ to ≥4 \* LLOQ if Baseline nAb level was \< LLOQ, or ≥4-fold rise if Baseline nAb level was ≥ LLOQ. PP Set included all randomized participants who received the study intervention, complied with the injection schedule, complied with the timings of immunogenicity blood sampling to have a Baseline and at least 1 post-injection assessment at Day 29, had no documented infection of either influenza or SARS-CoV-2 on Day 1 and up to Day 29, had no major dosing error, and had no major protocol deviations or conditions/medications that affected the immune response.

    Time frame: Baseline (Day 1) to Day 181

07

Results

Posted Dec 23, 2025

Participant flow

Participant flow — Overall Study
MilestonePart 1 Cohort A12: Influenza Vaccine 1Part 1 Cohort A13: Influenza Vaccine 2Part 1 Cohort A11: Investigational Influenza Vaccine 2Part 1 Cohort A8: Investigational Influenza Vaccine 1Part 1 Cohort A10: COVID-19 Vaccine 1Part 1 Cohort A9: Investigational COVID-19 Vaccine 1Part 1 Cohort A2: mRNA-1083.1 Dose Level 2Part 1 Cohort A3: mRNA-1083.1 Dose Level 3Part 1 Cohort A4: mRNA-1083.2 Dose Level 1Part 1 Cohort A5: mRNA-1083.2 Dose Level 2Part 1 Cohort A6: mRNA-1083.2 Dose Level 3Part 1 Cohort A7: mRNA-1083.3Part 1 Cohort B12: Influenza Vaccine 1Part 1 Cohort B11: Investigational Influenza Vaccine 2Part 1 Cohort B8: Investigational Influenza Vaccine 1Part 1 Cohort B10: COVID-19 Vaccine 1Part 1 Cohort B9: Investigational COVID-19 Vaccine 1Part 1 Cohort B1: mRNA-1083.1 Dose Level 1Part 1 Cohort B2: mRNA-1083.1 Dose Level 2Part 1 Cohort B3: mRNA-1083.1 Dose Level 3Part 1 Cohort B4: mRNA-1083.2 Dose Level 1Part 1 Cohort B5: mRNA-1083.2 Dose Level 2Part 1 Cohort B6: mRNA-1083.2 Dose Level 3Part 1 Cohort B7: mRNA-1083.3Part 2: Influenza Vaccine 1Part 2: Investigational Influenza Vaccine 1 Dose Level 1Part 2: Investigational Influenza Vaccine 1 Dose Level 2Part 2: COVID-19 Vaccine 2Part 2: Investigational COVID-19 Vaccine 2Part 2: mRNA-1083 Composition 1 Dose Level 1Part 2: mRNA-1083 Composition 1 Dose Level 2Part 2: mRNA-1083 Composition 1 Dose Level 3Part 2: mRNA-1083 Composition 1 Dose Level 4Part 2: mRNA-1083 Composition 2 Dose Level 1Part 2: mRNA-1083 Composition 2 Dose Level 2Part 2: mRNA-1083 Composition 2 Dose Level 3Part 2: mRNA-1083 Composition 2 Dose Level 4
Started54535453545252335454335352565656555656375556385641404042404042424140404042
Received study injection54535451545251335454335352555553555556375555385440394042404042414140404042
Safety set54535451545251335553335352555553555655375654385440394042404042414140404042
Solicited safety set54535451545251335553335352555553555655375654385340394042404042414140404042
Per protocol set51505045514950305351315050485250535153365052385138383740383942403940383342
Full analysis set (fas)54535451545251335454335352555553555556375555385440394042404042414140404042
Completed52535351545151335454335350535552525555375353365338383640383937393838393737
Not completed2012011000002314311023233242215332135
Withdrew: Lost to follow-up1000010000001101200012112141215032134
Withdrew: Withdrawal by subject1011000000001112110010021001000200001
Withdrew: Other than specified0001001000000101000001100100000100000
Withdrew: Physician decision0000000000000000001000000000000000000

Outcome measures

PrimaryParts 1 and 2: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)

Solicited ARs (local and systemic) were reported by participants an electronic diary (eDiary). Local ARs included: injection site pain, injection site erythema (redness), injection site swelling/induration (hardness), and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs included: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills.

Time frame:
Up to 7 days after study injection
Reported as:
Count of participants · Participants
Parts 1 and 2: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)
ParticipantsPart 1 Cohort A12: Influenza Vaccine 1Part 1 Cohort A13: Influenza Vaccine 2Part 1 Cohort A11: Investigational Influenza Vaccine 2Part 1 Cohort A8: Investigational Influenza Vaccine 1Part 1 Cohort A10: COVID-19 Vaccine 1Part 1 Cohort A9: Investigational COVID-19 Vaccine 1Part 1 Cohort A2: mRNA-1083.1 Dose Level 2Part 1 Cohort A3: mRNA-1083.1 Dose Level 3Part 1 Cohort A4: mRNA-1083.2 Dose Level 1Part 1 Cohort A5: mRNA-1083.2 Dose Level 2Part 1 Cohort A6: mRNA-1083.2 Dose Level 3Part 1 Cohort A7: mRNA-1083.3Part 1 Cohort B12: Influenza Vaccine 1Part 1 Cohort B11: Investigational Influenza Vaccine 2Part 1 Cohort B8: Investigational Influenza Vaccine 1Part 1 Cohort B10: COVID-19 Vaccine 1Part 1 Cohort B9: Investigational COVID-19 Vaccine 1Part 1 Cohort B1: mRNA-1083.1 Dose Level 1Part 1 Cohort B2: mRNA-1083.1 Dose Level 2Part 1 Cohort B3: mRNA-1083.1 Dose Level 3Part 1 Cohort B4: mRNA-1083.2 Dose Level 1Part 1 Cohort B5: mRNA-1083.2 Dose Level 2Part 1 Cohort B6: mRNA-1083.2 Dose Level 3Part 1 Cohort B7: mRNA-1083.3Part 2: Influenza Vaccine 1Part 2: Investigational Influenza Vaccine 1 Dose Level 1Part 2: Investigational Influenza Vaccine 1 Dose Level 2Part 2: COVID-19 Vaccine 2Part 2: Investigational COVID-19 Vaccine 2Part 2: mRNA-1083 Composition 1 Dose Level 1Part 2: mRNA-1083 Composition 1 Dose Level 2Part 2: mRNA-1083 Composition 1 Dose Level 3Part 2: mRNA-1083 Composition 1 Dose Level 4Part 2: mRNA-1083 Composition 2 Dose Level 1Part 2: mRNA-1083 Composition 2 Dose Level 2Part 2: mRNA-1083 Composition 2 Dose Level 3Part 2: mRNA-1083 Composition 2 Dose Level 4
Parts 1 and 2: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)32363743423144264246294633495146414750344651384732323940343439373833343739
PrimaryParts 1 and 2: Number of Participants With Unsolicited Adverse Events (AEs) and Severe AEs

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. Severity for all unsolicited AEs was determined by the Investigator based upon medical judgment and graded as Mild, Moderate or Severe. Number of participants with unsolicited AEs (SAEs and non-serious AEs) and severe AEs up to 28 days post-vaccination are reported in this outcome measure. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

Time frame:
Up to 28 days after study injection
Reported as:
Count of participants · Participants
Parts 1 and 2: Number of Participants With Unsolicited Adverse Events (AEs) and Severe AEs
ParticipantsPart 1 Cohort A12: Influenza Vaccine 1Part 1 Cohort A13: Influenza Vaccine 2Part 1 Cohort A11: Investigational Influenza Vaccine 2Part 1 Cohort A8: Investigational Influenza Vaccine 1Part 1 Cohort A10: COVID-19 Vaccine 1Part 1 Cohort A9: Investigational COVID-19 Vaccine 1Part 1 Cohort A2: mRNA-1083.1 Dose Level 2Part 1 Cohort A3: mRNA-1083.1 Dose Level 3Part 1 Cohort A4: mRNA-1083.2 Dose Level 1Part 1 Cohort A5: mRNA-1083.2 Dose Level 2Part 1 Cohort A6: mRNA-1083.2 Dose Level 3Part 1 Cohort A7: mRNA-1083.3Part 1 Cohort B12: Influenza Vaccine 1Part 1 Cohort B11: Investigational Influenza Vaccine 2Part 1 Cohort B8: Investigational Influenza Vaccine 1Part 1 Cohort B10: COVID-19 Vaccine 1Part 1 Cohort B9: Investigational COVID-19 Vaccine 1Part 1 Cohort B1: mRNA-1083.1 Dose Level 1Part 1 Cohort B2: mRNA-1083.1 Dose Level 2Part 1 Cohort B3: mRNA-1083.1 Dose Level 3Part 1 Cohort B4: mRNA-1083.2 Dose Level 1Part 1 Cohort B5: mRNA-1083.2 Dose Level 2Part 1 Cohort B6: mRNA-1083.2 Dose Level 3Part 1 Cohort B7: mRNA-1083.3Part 2: Influenza Vaccine 1Part 2: Investigational Influenza Vaccine 1 Dose Level 1Part 2: Investigational Influenza Vaccine 1 Dose Level 2Part 2: COVID-19 Vaccine 2Part 2: Investigational COVID-19 Vaccine 2Part 2: mRNA-1083 Composition 1 Dose Level 1Part 2: mRNA-1083 Composition 1 Dose Level 2Part 2: mRNA-1083 Composition 1 Dose Level 3Part 2: mRNA-1083 Composition 1 Dose Level 4Part 2: mRNA-1083 Composition 2 Dose Level 1Part 2: mRNA-1083 Composition 2 Dose Level 2Part 2: mRNA-1083 Composition 2 Dose Level 3Part 2: mRNA-1083 Composition 2 Dose Level 4
Unsolicited AEs597579726658511898116668855364443365458
Severe AEs0101102000000000000000001001000000000
PrimaryParts 1 and 2: Number of Participants With Unsolicited Medically Attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), Serious Adverse Events (SAEs), and AEs Leading to Study Discontinuation

An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability/permanent damage, was a congenital anomaly/birth defect, or was an important medical event. AESIs were protocol-defined medical concepts. An MAAE is an AE that lead to an unscheduled visit to an healthcare practitioner. This included visits to a study site for unscheduled assessments (for example, abnormal laboratory follow-up, and/or COVID-19 and visits to healthcare practitioners external to the study site. Number of participants with SAEs, AESIs, MAAEs, and AEs leading to study discontinuation up to Day 181 are reported in this outcome measure. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

Time frame:
Day 1 through Day 181
Reported as:
Count of participants · Participants
Parts 1 and 2: Number of Participants With Unsolicited Medically Attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), Serious Adverse Events (SAEs), and AEs Leading to Study Discontinuation
ParticipantsPart 1 Cohort A12: Influenza Vaccine 1Part 1 Cohort A13: Influenza Vaccine 2Part 1 Cohort A11: Investigational Influenza Vaccine 2Part 1 Cohort A8: Investigational Influenza Vaccine 1Part 1 Cohort A10: COVID-19 Vaccine 1Part 1 Cohort A9: Investigational COVID-19 Vaccine 1Part 1 Cohort A2: mRNA-1083.1 Dose Level 2Part 1 Cohort A3: mRNA-1083.1 Dose Level 3Part 1 Cohort A4: mRNA-1083.2 Dose Level 1Part 1 Cohort A5: mRNA-1083.2 Dose Level 2Part 1 Cohort A6: mRNA-1083.2 Dose Level 3Part 1 Cohort A7: mRNA-1083.3Part 1 Cohort B12: Influenza Vaccine 1Part 1 Cohort B11: Investigational Influenza Vaccine 2Part 1 Cohort B8: Investigational Influenza Vaccine 1Part 1 Cohort B10: COVID-19 Vaccine 1Part 1 Cohort B9: Investigational COVID-19 Vaccine 1Part 1 Cohort B1: mRNA-1083.1 Dose Level 1Part 1 Cohort B2: mRNA-1083.1 Dose Level 2Part 1 Cohort B3: mRNA-1083.1 Dose Level 3Part 1 Cohort B4: mRNA-1083.2 Dose Level 1Part 1 Cohort B5: mRNA-1083.2 Dose Level 2Part 1 Cohort B6: mRNA-1083.2 Dose Level 3Part 1 Cohort B7: mRNA-1083.3Part 2: Influenza Vaccine 1Part 2: Investigational Influenza Vaccine 1 Dose Level 1Part 2: Investigational Influenza Vaccine 1 Dose Level 2Part 2: COVID-19 Vaccine 2Part 2: Investigational COVID-19 Vaccine 2Part 2: mRNA-1083 Composition 1 Dose Level 1Part 2: mRNA-1083 Composition 1 Dose Level 2Part 2: mRNA-1083 Composition 1 Dose Level 3Part 2: mRNA-1083 Composition 1 Dose Level 4Part 2: mRNA-1083 Composition 2 Dose Level 1Part 2: mRNA-1083 Composition 2 Dose Level 2Part 2: mRNA-1083 Composition 2 Dose Level 3Part 2: mRNA-1083 Composition 2 Dose Level 4
SAEs2211212011111210010110121110010100010
AESIs3120212010101012021010020100010100000
MAAEs1116131613201241214710131313171715109101312587688106116111098
AEs Leading to Study Discontinuation00000000000000000000000000000000000000
PrimaryPart 2: Geometric Mean Titer (GMT) of Antibodies for Influenza at Day 29, as Measured by Hemagglutination Inhibition (HAI) Assay

Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. Antibody values reported as below the lower limit of quantification (LLOQ) were replaced by 0.5 \* LLOQ. Values greater than the upper limit of quantification (ULOQ) were converted to the ULOQ. LLOQ = 10 and ULOQ = 3620 for Influenza A H1N1 antibody, LLOQ = 10 and ULOQ = 5120 for Influenza A H3N2 antibody, LLOQ = 10 and ULOQ = 1356 for Influenza B/Victoria-lineage antibody, and LLOQ = 10 and ULOQ = 1280 for Influenza B/Yamagata-lineage antibody. 95% confidence interval (CI) was calculated based on the t-distribution of the log-transformed values for geometric mean (GM) titer, then back transformed to the original scale for presentation. Arms based on the applicable vaccine for this Outcome Measure.

Time frame:
Day 29
Reported as:
Geometric mean · titer
Part 2: Geometric Mean Titer (GMT) of Antibodies for Influenza at Day 29, as Measured by Hemagglutination Inhibition (HAI) Assay
titerPart 2: Influenza Vaccine 1Part 2: Investigational Influenza Vaccine 1 Dose Level 1Part 2: Investigational Influenza Vaccine 1 Dose Level 2Part 2: mRNA-1083 Composition 1 Dose Level 1Part 2: mRNA-1083 Composition 1 Dose Level 2Part 2: mRNA-1083 Composition 1 Dose Level 3Part 2: mRNA-1083 Composition 1 Dose Level 4Part 2: mRNA-1083 Composition 2 Dose Level 1Part 2: mRNA-1083 Composition 2 Dose Level 2Part 2: mRNA-1083 Composition 2 Dose Level 3Part 2: mRNA-1083 Composition 2 Dose Level 4
Influenza A H1N1 Antibody80.0 (50.3 to 127.2)105.1 (71.9 to 153.7)129.0 (86.2 to 193.1)73.9 (52.6 to 103.6)98.3 (71.3 to 135.5)111.2 (81.2 to 152.5)99.9 (69.6 to 143.4)85.7 (61.0 to 120.4)88.4 (64.3 to 121.5)71.2 (47.6 to 106.7)106.0 (73.3 to 153.2)
Influenza A H3N2 Antibody80.7 (60.9 to 107.0)96.0 (66.3 to 139.1)155.6 (111.4 to 217.3)65.8 (50.3 to 86.1)71.3 (53.9 to 94.2)105.6 (80.2 to 139.0)79.3 (59.5 to 105.7)62.2 (45.5 to 85.1)79.3 (61.8 to 101.7)75.2 (54.0 to 104.5)80.7 (64.5 to 100.8)
Influenza B/Victoria-lineage Antibody86.0 (67.7 to 109.2)80.7 (59.5 to 109.5)141.9 (100.3 to 200.8)75.8 (57.4 to 100.2)104.2 (81.1 to 133.8)108.4 (84.2 to 139.5)106.3 (76.4 to 147.9)98.5 (72.2 to 134.3)78.5 (61.3 to 100.6)75.9 (56.7 to 101.6)82.0 (63.8 to 105.5)
Influenza B/Yamagata-lineage Antibody140.8 (110.2 to 179.9)122.8 (99.2 to 151.9)179.0 (130.4 to 245.7)80.7 (64.1 to 101.7)101.6 (80.0 to 129.0)112.2 (87.8 to 143.3)112.2 (90.1 to 139.7)94.3 (69.6 to 127.9)118.3 (87.4 to 160.3)97.7 (74.8 to 127.5)98.3 (76.5 to 126.2)
PrimaryPart 2: GM Concentration of Antibodies for SARS-CoV-2 at Day 29, as Measured by Pseudovirus Neutralization Assay (PsVNA)

SARS-CoV-2 strain included Omicron XBB.1.5 antibody. Antibody values reported as below the LLOQ are replaced by 0.5 \* LLOQ. Values greater than the ULOQ are converted to the ULOQ. LLOQ = 38 and ULOQ = 6960 arbitrary units (AU)/milliliter (mL) for SARS-CoV-2 Omicron XBB.1.5 antibody. 95% CI was calculated based on the t-distribution of the log-transformed values for GM concentration, then back transformed to the original scale for presentation. Arms based on the applicable vaccine for this Outcome Measure.

Time frame:
Day 29
Reported as:
Geometric mean · AU/mL
Part 2: GM Concentration of Antibodies for SARS-CoV-2 at Day 29, as Measured by Pseudovirus Neutralization Assay (PsVNA)
AU/mLPart 2: COVID-19 Vaccine 2Part 2: Investigational COVID-19 Vaccine 2Part 2: mRNA-1083 Composition 1 Dose Level 1Part 2: mRNA-1083 Composition 1 Dose Level 2Part 2: mRNA-1083 Composition 1 Dose Level 3Part 2: mRNA-1083 Composition 1 Dose Level 4Part 2: mRNA-1083 Composition 2 Dose Level 1Part 2: mRNA-1083 Composition 2 Dose Level 2Part 2: mRNA-1083 Composition 2 Dose Level 3Part 2: mRNA-1083 Composition 2 Dose Level 4
Part 2: GM Concentration of Antibodies for SARS-CoV-2 at Day 29, as Measured by Pseudovirus Neutralization Assay (PsVNA)1567.0 (1134.6 to 2164.4)1939.7 (1366.0 to 2754.4)427.6 (302.9 to 603.7)901.0 (655.9 to 1237.6)882.0 (630.5 to 1233.9)1108.3 (801.9 to 1531.7)679.7 (451.4 to 1023.4)878.7 (640.1 to 1206.2)904.8 (576.5 to 1420.1)1083.7 (744.2 to 1578.3)
PrimaryPart 2: Geometric Mean Fold-Rise (GMFR) of Antibodies for Influenza at Day 29, as Measured by HAI Assay

Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were converted to the ULOQ. LLOQ = 10 and ULOQ = 3620 for Influenza A H1N1 antibody, LLOQ = 10 and ULOQ = 5120 for Influenza A H3N2 antibody, LLOQ = 10 and ULOQ = 1356 for Influenza B/Victoria-lineage antibody, and LLOQ = 10 and ULOQ = 1280 for Influenza B/Yamagata-lineage antibody. 95% CI was calculated based on the t-distribution of the log-transformed values for GMFR values, then back transformed to the original scale for presentation. Arms based on the applicable vaccine for this Outcome Measure.

Time frame:
Day 29
Reported as:
Geometric mean · ratio
Part 2: Geometric Mean Fold-Rise (GMFR) of Antibodies for Influenza at Day 29, as Measured by HAI Assay
ratioPart 2: Influenza Vaccine 1Part 2: Investigational Influenza Vaccine 1 Dose Level 1Part 2: Investigational Influenza Vaccine 1 Dose Level 2Part 2: mRNA-1083 Composition 1 Dose Level 1Part 2: mRNA-1083 Composition 1 Dose Level 2Part 2: mRNA-1083 Composition 1 Dose Level 3Part 2: mRNA-1083 Composition 1 Dose Level 4Part 2: mRNA-1083 Composition 2 Dose Level 1Part 2: mRNA-1083 Composition 2 Dose Level 2Part 2: mRNA-1083 Composition 2 Dose Level 3Part 2: mRNA-1083 Composition 2 Dose Level 4
Influenza A H1N1 Antibody2.6 (1.8 to 3.9)3.5 (2.5 to 4.8)3.7 (2.6 to 5.2)1.8 (1.4 to 2.2)2.2 (1.7 to 2.8)2.7 (1.9 to 3.9)2.0 (1.6 to 2.5)1.9 (1.3 to 2.7)2.7 (2.0 to 3.7)2.3 (1.6 to 3.1)2.9 (2.2 to 3.7)
Influenza A H3N2 Antibody2.8 (2.2 to 3.7)2.6 (2.1 to 3.3)3.4 (2.5 to 4.6)1.8 (1.4 to 2.3)1.9 (1.6 to 2.4)2.3 (1.7 to 3.1)2.0 (1.5 to 2.7)1.7 (1.4 to 2.1)2.3 (1.9 to 2.7)1.8 (1.3 to 2.4)2.7 (2.2 to 3.3)
Influenza B/Victoria-lineage Antibody1.7 (1.4 to 2.1)2.0 (1.5 to 2.6)2.4 (1.7 to 3.2)1.4 (1.2 to 1.7)1.6 (1.3 to 1.9)1.7 (1.5 to 2.1)2.1 (1.7 to 2.6)1.5 (1.2 to 1.8)1.5 (1.3 to 1.7)1.5 (1.3 to 1.9)1.7 (1.4 to 2.1)
Influenza B/Yamagata-lineage Antibody1.7 (1.4 to 2.2)2.3 (1.8 to 2.8)2.1 (1.7 to 2.7)1.3 (1.1 to 1.5)1.4 (1.2 to 1.7)1.6 (1.3 to 2.0)1.6 (1.4 to 1.9)1.3 (1.1 to 1.6)1.6 (1.3 to 2.0)1.4 (1.2 to 1.8)1.6 (1.3 to 1.8)
PrimaryPart 2: GMFR of Antibodies for SARS-CoV-2 at Day 29, as Measured by PsVNA

SARS-CoV-2 strain included Omicron XBB.1.5 antibody. Antibody values reported as below the LLOQ are replaced by 0.5 \* LLOQ. Values greater than the ULOQ are converted to the ULOQ. LLOQ = 38 and ULOQ = 6960 AU/mL for SARS-CoV-2 Omicron XBB.1.5 antibody. 95% CI was calculated based on the t-distribution of the log-transformed values for GMFR values, then back transformed to the original scale for presentation. Arms based on the applicable vaccine for this Outcome Measure.

Time frame:
Day 29
Reported as:
Geometric mean · ratio
Part 2: GMFR of Antibodies for SARS-CoV-2 at Day 29, as Measured by PsVNA
ratioPart 2: COVID-19 Vaccine 2Part 2: Investigational COVID-19 Vaccine 2Part 2: mRNA-1083 Composition 1 Dose Level 1Part 2: mRNA-1083 Composition 1 Dose Level 2Part 2: mRNA-1083 Composition 1 Dose Level 3Part 2: mRNA-1083 Composition 1 Dose Level 4Part 2: mRNA-1083 Composition 2 Dose Level 1Part 2: mRNA-1083 Composition 2 Dose Level 2Part 2: mRNA-1083 Composition 2 Dose Level 3Part 2: mRNA-1083 Composition 2 Dose Level 4
Part 2: GMFR of Antibodies for SARS-CoV-2 at Day 29, as Measured by PsVNA5.4 (3.3 to 8.7)9.1 (5.4 to 15.2)3.3 (2.1 to 5.2)5.4 (3.5 to 8.1)4.4 (2.9 to 6.9)3.6 (2.5 to 5.1)4.5 (2.9 to 6.9)4.1 (2.9 to 6.0)7.1 (4.4 to 11.4)8.0 (5.4 to 11.7)
PrimaryPart 2: Influenza: Percentage of Participants With Seroconversion, as Measured by HAI Assay

Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. Seroconversion was defined as a pre-vaccination HAI titer \<1:10 and a post-vaccination HAI titer ≥1:40 or a pre-vaccination HAI titer ≥1:10 and a minimum 4-fold rise in post-vaccination HAI antibody titer. Arms based on the applicable vaccine for this Outcome Measure.

Time frame:
Baseline to Day 29
Reported as:
Number · percentage of participants
Part 2: Influenza: Percentage of Participants With Seroconversion, as Measured by HAI Assay
percentage of participantsPart 2: Influenza Vaccine 1Part 2: Investigational Influenza Vaccine 1 Dose Level 1Part 2: Investigational Influenza Vaccine 1 Dose Level 2Part 2: mRNA-1083 Composition 1 Dose Level 1Part 2: mRNA-1083 Composition 1 Dose Level 2Part 2: mRNA-1083 Composition 1 Dose Level 3Part 2: mRNA-1083 Composition 1 Dose Level 4Part 2: mRNA-1083 Composition 2 Dose Level 1Part 2: mRNA-1083 Composition 2 Dose Level 2Part 2: mRNA-1083 Composition 2 Dose Level 3Part 2: mRNA-1083 Composition 2 Dose Level 4
Influenza A H1N1 Antibody31.6 (17.5 to 48.7)50.0 (33.4 to 66.6)51.4 (34.4 to 68.1)17.9 (7.5 to 33.5)31.0 (17.6 to 47.1)30.0 (16.6 to 46.5)25.6 (13.0 to 42.1)17.5 (7.3 to 32.8)34.2 (19.6 to 51.4)30.3 (15.6 to 48.7)35.7 (21.6 to 52.0)
Influenza A H3N2 Antibody42.1 (26.3 to 59.2)36.8 (21.8 to 54.0)43.2 (27.1 to 60.5)12.8 (4.3 to 27.4)23.8 (12.1 to 39.5)27.5 (14.6 to 43.9)23.1 (11.1 to 39.3)15.0 (5.7 to 29.8)21.1 (9.6 to 37.3)21.2 (9.0 to 38.9)42.9 (27.7 to 59.0)
Influenza B/Victoria-lineage Antibody15.8 (6.0 to 31.3)15.8 (6.0 to 31.3)27.0 (13.8 to 44.1)7.7 (1.6 to 20.9)9.5 (2.7 to 22.6)12.5 (4.2 to 26.8)23.1 (11.1 to 39.3)12.5 (4.2 to 26.8)2.6 (0.1 to 13.8)9.1 (1.9 to 24.3)11.9 (4.0 to 25.6)
Influenza B/Yamagata-lineage Antibody21.1 (9.6 to 37.3)26.3 (13.4 to 43.1)27.0 (13.8 to 44.1)7.7 (1.6 to 20.9)9.5 (2.7 to 22.6)12.5 (4.2 to 26.8)7.7 (1.6 to 20.9)17.5 (7.3 to 32.8)13.2 (4.4 to 28.1)9.1 (1.9 to 24.3)4.8 (0.6 to 16.2)
PrimaryPart 2: SARS-CoV-2: Percentage of Participants With Seroresponse, as Measured by PsVNA

SARS-CoV-2 strain included Omicron XBB.1.5 antibody. Seroresponse was defined as an increase from below the LLOQ to ≥4 \* LLOQ if Baseline neutralizing antibody (nAb) level was \< LLOQ, or ≥4-fold rise if Baseline nAb level was ≥ LLOQ. LLOQ = 38 and ULOQ = 6960 AU/mL for SARS-CoV-2 Omicron XBB.1.5 antibody. Arms based on the applicable vaccine for this Outcome Measure.

Time frame:
Baseline to Day 29
Reported as:
Number · percentage of participants
Part 2: SARS-CoV-2: Percentage of Participants With Seroresponse, as Measured by PsVNA
percentage of participantsPart 2: COVID-19 Vaccine 2Part 2: Investigational COVID-19 Vaccine 2Part 2: mRNA-1083 Composition 1 Dose Level 1Part 2: mRNA-1083 Composition 1 Dose Level 2Part 2: mRNA-1083 Composition 1 Dose Level 3Part 2: mRNA-1083 Composition 1 Dose Level 4Part 2: mRNA-1083 Composition 2 Dose Level 1Part 2: mRNA-1083 Composition 2 Dose Level 2Part 2: mRNA-1083 Composition 2 Dose Level 3Part 2: mRNA-1083 Composition 2 Dose Level 4
Part 2: SARS-CoV-2: Percentage of Participants With Seroresponse, as Measured by PsVNA55.0 (38.5 to 70.7)57.9 (40.8 to 73.7)33.3 (19.1 to 50.2)52.4 (36.4 to 68.0)47.5 (31.5 to 63.9)33.3 (19.1 to 50.2)50.0 (33.8 to 66.2)44.7 (28.6 to 61.7)63.6 (45.1 to 79.6)69.0 (52.9 to 82.4)
SecondaryPart 1: GMT of Antibodies for Influenza, as Measured by HAI Assay

Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. Antibody values reported as below LLOQ were replaced by 0.5 \* LLOQ. Values greater than ULOQ were converted to ULOQ. LLOQ = 10 and ULOQ = 640 for Influenza A H1N1 and Influenza A H3N2 antibody, LLOQ = 10 and ULOQ = 320 for Influenza B/ Victoria, and LLOQ = 10 and ULOQ = 640 for Influenza B/Yamagata antibody. 95% CI was calculated based on t-distribution of log-transformed values for GM titer, then back transformed to original scale for presentation. PP Set: all randomized participants who received study drug, complied with injection schedule, complied with timings of immunogenicity blood sampling to have a Baseline and at least 1 post-injection assessment at Day 29, had no documented infection of either influenza or SARS-CoV-2 on Day 1 and up to Day 29, had no major dosing error, and had no major protocol deviations or conditions/medications that affected immune response.

Time frame:
Baseline (Day 1), Day 29, and Day 181
Reported as:
Geometric mean · titer
Part 1: GMT of Antibodies for Influenza, as Measured by HAI Assay
titerPart 1 Cohort A12: Influenza Vaccine 1Part 1 Cohort A13: Influenza Vaccine 2Part 1 Cohort A11: Investigational Influenza Vaccine 2Part 1 Cohort A8: Investigational Influenza Vaccine 1Part 1 Cohort A2: mRNA-1083.1 Dose Level 2Part 1 Cohort A3: mRNA-1083.1 Dose Level 3Part 1 Cohort A4: mRNA-1083.2 Dose Level 1Part 1 Cohort A5: mRNA-1083.2 Dose Level 2Part 1 Cohort A6: mRNA-1083.2 Dose Level 3Part 1 Cohort A7: mRNA-1083.3Part 1 Cohort B12: Influenza Vaccine 1Part 1 Cohort B11: Investigational Influenza Vaccine 2Part 1 Cohort B8: Investigational Influenza Vaccine 1Part 1 Cohort B1: mRNA-1083.1 Dose Level 1Part 1 Cohort B2: mRNA-1083.1 Dose Level 2Part 1 Cohort B3: mRNA-1083.1 Dose Level 3Part 1 Cohort B4: mRNA-1083.2 Dose Level 1Part 1 Cohort B5: mRNA-1083.2 Dose Level 2Part 1 Cohort B6: mRNA-1083.2 Dose Level 3Part 1 Cohort B7: mRNA-1083.3
Influenza A H1N1 Antibody: Day 149.7 (40.4 to 61.1)47.5 (36.9 to 61.2)55.0 (42.3 to 71.6)55.7 (43.3 to 71.6)58.2 (46.3 to 73.1)41.4 (29.0 to 59.2)55.1 (41.1 to 73.9)53.1 (39.5 to 71.3)39.1 (29.7 to 51.6)57.7 (46.1 to 72.4)48.3 (38.5 to 60.6)61.8 (47.2 to 81.0)48.9 (38.8 to 61.7)51.4 (38.5 to 68.8)57.3 (45.6 to 72.0)59.4 (44.2 to 79.7)52.7 (40.8 to 68.2)58.5 (47.0 to 72.8)77.0 (55.9 to 106.1)58.5 (44.8 to 76.3)
Influenza A H1N1 Antibody: Day 2978.4 (60.9 to 100.8)85.7 (62.9 to 116.8)108.5 (84.0 to 140.1)149.3 (107.5 to 207.3)95.8 (74.8 to 122.8)104.3 (69.4 to 156.8)106.0 (81.5 to 137.9)139.5 (99.9 to 194.9)82.7 (56.3 to 121.3)129.1 (99.9 to 166.8)114.0 (82.1 to 158.3)145.3 (105.1 to 200.9)138.2 (101.7 to 187.7)126.4 (98.3 to 162.5)120.8 (89.7 to 162.6)135.9 (101.5 to 181.9)177.6 (135.6 to 232.4)142.9 (115.1 to 177.3)196.7 (138.2 to 280.1)150.5 (115.0 to 197.0)
Influenza A H1N1 Antibody: Day 181104.5 (80.1 to 136.3)104.7 (74.8 to 146.7)99.3 (74.0 to 133.3)148.1 (99.2 to 221.1)104.3 (77.6 to 140.3)145.6 (104.1 to 203.7)127.3 (96.2 to 168.5)135.3 (102.4 to 178.7)104.2 (73.7 to 147.2)140.2 (108.9 to 180.5)118.4 (88.4 to 158.7)140.6 (108.1 to 182.8)174.5 (137.5 to 221.5)134.5 (104.6 to 173.0)147.9 (113.0 to 193.5)157.9 (111.4 to 223.8)176.3 (134.6 to 230.8)132.5 (105.9 to 165.9)156.1 (114.5 to 212.9)161.2 (121.6 to 213.8)
Influenza A H3N2 Antibody: Day 134.4 (25.5 to 46.6)34.1 (26.5 to 43.9)38.9 (29.3 to 51.5)30.7 (23.0 to 41.0)43.1 (33.9 to 54.9)31.7 (22.4 to 44.8)29.0 (21.4 to 39.5)37.6 (27.4 to 51.5)39.6 (28.3 to 55.2)32.1 (24.0 to 43.0)27.5 (21.3 to 35.5)48.3 (34.7 to 67.3)43.9 (33.2 to 58.1)38.9 (29.9 to 50.6)30.0 (23.9 to 37.6)36.0 (26.1 to 49.7)32.0 (23.4 to 43.9)43.0 (31.3 to 59.2)34.8 (25.9 to 46.7)33.2 (25.3 to 43.4)
Influenza A H3N2 Antibody: Day 2961.8 (45.6 to 83.8)67.7 (48.9 to 93.8)88.3 (65.7 to 118.6)113.2 (77.6 to 165.0)90.7 (65.6 to 125.2)119.8 (74.9 to 191.7)64.8 (47.8 to 87.9)103.4 (78.1 to 136.9)94.6 (63.8 to 140.2)100.6 (75.5 to 134.1)64.5 (45.8 to 90.9)111.5 (84.8 to 146.7)117.8 (83.2 to 166.6)105.6 (79.4 to 140.3)73.0 (52.9 to 100.8)104.8 (70.3 to 156.0)116.3 (84.2 to 160.6)107.2 (77.7 to 147.8)93.8 (66.2 to 132.9)110.8 (78.8 to 155.9)
Influenza A H3N2 Antibody: Day 18185.1 (64.2 to 112.9)87.2 (63.2 to 120.3)116.9 (80.0 to 170.7)146.7 (99.3 to 216.9)129.8 (96.2 to 175.2)196.4 (125.1 to 308.5)91.5 (71.5 to 117.0)114.2 (81.4 to 160.2)107.2 (72.5 to 158.5)117.9 (87.1 to 159.6)83.2 (64.9 to 106.6)111.2 (87.2 to 141.9)140.0 (93.9 to 208.6)129.4 (99.5 to 168.4)102.1 (73.7 to 141.5)149.3 (95.1 to 234.2)120.8 (87.8 to 166.2)145.7 (111.0 to 191.2)111.7 (79.7 to 156.7)134.1 (98.6 to 182.3)
Influenza B/Victoria-lineage Antibody: Day 155.4 (41.3 to 74.3)49.2 (35.8 to 67.8)46.7 (34.0 to 64.2)46.8 (34.5 to 63.4)73.1 (56.4 to 94.7)52.2 (36.7 to 74.3)72.5 (56.2 to 93.7)55.0 (41.3 to 73.0)46.8 (32.5 to 67.3)69.6 (52.3 to 92.8)34.5 (25.7 to 46.4)33.1 (23.5 to 46.6)31.5 (23.3 to 42.6)37.6 (28.5 to 49.6)39.0 (29.2 to 52.0)34.3 (23.3 to 50.4)35.3 (25.1 to 49.5)36.9 (28.2 to 48.4)33.0 (24.7 to 44.1)39.4 (28.6 to 54.4)
Influenza B/Victoria-lineage Antibody: Day 29100.7 (70.1 to 144.8)106.3 (72.7 to 155.3)88.3 (65.3 to 119.4)151.5 (120.5 to 190.5)141.2 (107.9 to 184.9)128.5 (82.0 to 201.3)148.0 (115.3 to 189.9)155.5 (121.1 to 199.6)152.9 (106.7 to 219.1)172.7 (131.9 to 226.0)83.4 (58.7 to 118.6)59.1 (44.7 to 78.2)83.8 (59.7 to 117.6)76.8 (59.5 to 99.1)96.7 (70.2 to 133.0)89.0 (62.1 to 127.7)76.1 (55.1 to 105.2)113.1 (82.1 to 155.9)91.2 (65.2 to 127.7)93.5 (67.1 to 130.3)
Influenza B/Victoria-lineage Antibody: Day 181167.2 (113.6 to 246.2)128.2 (86.3 to 190.6)95.1 (68.6 to 131.9)139.9 (108.0 to 181.1)140.6 (106.9 to 184.8)178.8 (110.4 to 289.4)174.5 (136.2 to 223.6)142.5 (101.1 to 200.9)183.7 (122.6 to 275.4)185.7 (136.2 to 253.1)103.2 (77.5 to 137.4)81.3 (58.0 to 113.9)115.9 (82.1 to 163.6)115.9 (86.8 to 154.6)126.3 (97.6 to 163.5)82.2 (53.0 to 127.5)86.0 (64.1 to 115.4)93.8 (73.0 to 120.4)99.9 (64.2 to 155.6)112.3 (81.4 to 155.0)
Influenza B/Yamagata-lineage Antibody: Day 149.0 (36.9 to 65.2)56.5 (43.0 to 74.3)62.9 (46.5 to 85.0)52.7 (39.7 to 70.0)80.6 (65.0 to 99.9)63.5 (45.3 to 88.9)74.5 (57.2 to 96.9)56.5 (42.8 to 74.7)48.4 (33.1 to 70.7)90.6 (68.8 to 119.4)78.3 (62.4 to 98.3)94.1 (74.0 to 119.6)85.5 (66.5 to 110.0)100.1 (74.0 to 135.4)91.1 (67.9 to 122.2)81.6 (60.9 to 109.3)74.7 (57.8 to 96.5)88.5 (67.6 to 115.8)101.1 (71.0 to 143.9)84.0 (62.2 to 113.5)
Influenza B/Yamagata-lineage Antibody: Day 2975.2 (56.2 to 100.7)110.0 (83.3 to 145.3)100.4 (75.9 to 132.8)108.1 (82.3 to 141.9)110.8 (86.9 to 141.3)101.9 (69.0 to 150.4)112.3 (83.3 to 151.5)98.7 (75.9 to 128.1)80.0 (56.5 to 113.3)145.2 (109.5 to 192.7)151.4 (108.7 to 210.8)165.9 (132.4 to 208.0)176.7 (129.5 to 241.3)185.0 (134.8 to 253.9)178.0 (139.7 to 226.7)145.3 (100.5 to 210.0)154.5 (118.2 to 202.0)181.5 (139.6 to 236.1)246.1 (175.8 to 344.6)154.7 (113.5 to 210.8)
Influenza B/Yamagata-lineage Antibody: Day 18194.8 (65.4 to 137.4)112.0 (78.2 to 160.5)84.5 (56.5 to 126.4)98.9 (68.6 to 142.5)109.6 (80.9 to 148.4)109.6 (71.7 to 167.6)98.9 (74.0 to 132.3)98.1 (68.4 to 140.9)87.3 (53.2 to 143.1)121.9 (87.6 to 169.6)88.4 (66.6 to 117.3)91.8 (69.2 to 121.8)121.4 (89.6 to 164.5)129.8 (95.6 to 176.1)121.4 (91.5 to 161.0)75.7 (50.2 to 114.1)112.2 (78.5 to 160.4)95.2 (72.9 to 124.1)111.7 (76.6 to 162.9)88.4 (66.6 to 117.5)
SecondaryPart 1: GMT of Antibodies for SARS-CoV-2, as Measured by PsVNA

SARS-CoV-2 strain included BA.4/5 and D614G antibody. Antibody values reported as below LLOQ were replaced by 0.5 \* LLOQ. Values greater than ULOQ were converted to ULOQ. LLOQ = 53 and ULOQ = 71376 for SARS-CoV-2 BA.4/5 antibody and LLOQ = 74.1 and ULOQ = 184317 for SARS-CoV-2 D614G antibody. 95% CI was calculated based on t-distribution of log-transformed values for GM titer, then back transformed to original scale for presentation. PP Set: all randomized participants who received study drug, complied with injection schedule, complied with timings of immunogenicity blood sampling to have a Baseline and at least 1 post-injection assessment at Day 29, had no documented infection of either influenza or SARS-CoV-2 on Day 1 and up to Day 29, had no major dosing error, and had no major protocol deviations or conditions/medications that affected immune response.

Time frame:
Baseline (Day 1), Day 29, and Day 181
Reported as:
Geometric mean · titer
Part 1: GMT of Antibodies for SARS-CoV-2, as Measured by PsVNA
titerPart 1 Cohort A10: COVID-19 Vaccine 1Part 1 Cohort A9: Investigational COVID-19 Vaccine 1Part 1 Cohort A2: mRNA-1083.1 Dose Level 2Part 1 Cohort A3: mRNA-1083.1 Dose Level 3Part 1 Cohort A4: mRNA-1083.2 Dose Level 1Part 1 Cohort A5: mRNA-1083.2 Dose Level 2Part 1 Cohort A6: mRNA-1083.2 Dose Level 3Part 1 Cohort A7: mRNA-1083.3Part 1 Cohort B10: COVID-19 Vaccine 1Part 1 Cohort B9: Investigational COVID-19 Vaccine 1Part 1 Cohort B1: mRNA-1083.1 Dose Level 1Part 1 Cohort B2: mRNA-1083.1 Dose Level 2Part 1 Cohort B3: mRNA-1083.1 Dose Level 3Part 1 Cohort B4: mRNA-1083.2 Dose Level 1Part 1 Cohort B5: mRNA-1083.2 Dose Level 2Part 1 Cohort B6: mRNA-1083.2 Dose Level 3Part 1 Cohort B7: mRNA-1083.3
SARS-CoV-2 BA.4/5 Antibody: Day 1618.0 (403.0 to 947.9)574.1 (352.8 to 848.2)616.9 (367.1 to 1036.8)585.9 (314.7 to 1090.6)646.6 (408.8 to 1022.7)536.3 (329.5 to 872.7)1008.2 (616.1 to 1649.7)883.2 (584.9 to 1333.6)384.1 (251.4 to 586.8)469.8 (297.5 to 741.8)653.7 (442.5 to 965.8)440.5 (295.7 to 656.3)487.5 (283.4 to 838.4)469.1 (292.1 to 753.2)524.8 (361.7 to 761.5)301.8 (195.0 to 467.1)489.8 (320.9 to 747.7)
SARS-CoV-2 BA.4/5 Antibody: Day 294536.9 (3147.0 to 6540.8)5476.9 (3988.2 to 7521.5)4636.7 (3098.6 to 6938.3)5387.3 (3207.7 to 9047.8)3706.0 (2656.8 to 5169.4)3669.6 (2577.8 to 5223.8)5647.8 (4227.0 to 7546.2)4120.6 (3224.4 to 5265.8)2635.8 (1973.8 to 3519.9)4743.9 (3529.0 to 6377.1)4005.9 (3131.4 to 5124.5)3061.1 (2308.3 to 4059.2)3599.0 (2577.6 to 5025.1)3425.6 (2558.6 to 4586.4)4391.3 (3488.0 to 5528.4)3119.7 (2360.0 to 4124.0)3458.4 (2595.9 to 4607.5)
SARS-CoV-2 BA.4/5 Antibody: Day 1811500.1 (977.6 to 2301.8)2524.4 (1588.3 to 4012.3)1793.9 (1145.8 to 2808.5)1851.8 (899.5 to 3812.3)1461.3 (945.9 to 2257.6)1552.5 (935.1 to 2577.6)2185.7 (1425.4 to 3351.4)1480.3 (980.2 to 2235.6)1443.0 (1049.6 to 1983.9)1972.1 (1305.9 to 2978.2)1595.9 (1167.3 to 2181.8)1225.0 (861.6 to 1741.6)1657.5 (999.9 to 2747.5)1413.4 (936.8 to 2132.5)1792.7 (1311.6 to 2450.4)1042.8 (620.3 to 1753.1)1270.3 (888.8 to 1815.5)
SARS-CoV-2 D614G Antibody: Day 12052.1 (1472.4 to 2860.0)2176.0 (1546.4 to 3062.0)2362.5 (1525.7 to 3658.3)2578.4 (1482.4 to 4484.8)2992.6 (2118.7 to 4226.9)2091.1 (1408.0 to 3105.7)3284.9 (2260.6 to 4773.3)2909.8 (2255.8 to 3753.4)1548.5 (1057.5 to 2267.5)1756.8 (1185.2 to 2604.2)2328.9 (1776.8 to 3052.6)1994.9 (1476.1 to 2696.1)1553.2 (1011.9 to 2384.1)1575.1 (1051.1 to 2360.4)2056.3 (1471.1 to 2874.2)1391.3 (986.7 to 1961.7)1527.4 (1057.0 to 2207.2)
SARS-CoV-2 D614G Antibody: Day 299943.4 (7910.9 to 12498.1)12229.6 (9571.1 to 15626.7)9275.7 (6926.0 to 12422.7)10433.9 (7040.4 to 15463.1)7678.3 (6034.4 to 9770.0)8513.1 (6542.0 to 11078.0)10057.5 (7712.1 to 13116.1)8639.7 (7025.9 to 10624.1)7038.1 (5592.1 to 8858.0)10243.2 (8204.9 to 12787.7)7431.1 (6091.6 to 9065.1)7127.4 (5855.8 to 8675.1)6525.4 (4850.0 to 8779.4)6738.9 (5281.8 to 8597.8)7844.9 (6467.6 to 9515.4)7333.0 (5842.7 to 9203.4)6877.4 (5218.1 to 9064.5)
SARS-CoV-2 D614G Antibody: Day 1813583.2 (2756.2 to 4658.4)5778.1 (4110.6 to 8121.9)4006.2 (2759.3 to 5816.7)3927.0 (2086.7 to 7390.1)3317.4 (2397.5 to 4590.2)3877.3 (2667.2 to 5636.2)5622.0 (3718.2 to 8500.5)3889.4 (2807.8 to 5387.6)3296.0 (2452.4 to 4429.8)4324.3 (3256.8 to 5741.6)3292.4 (2601.5 to 4166.7)3008.6 (2336.9 to 3873.5)2633.9 (1532.5 to 4527.0)2743.1 (1976.1 to 3807.9)2904.4 (2145.9 to 3931.1)1908.1 (1316.1 to 2766.3)2386.0 (1676.1 to 3396.6)
SecondaryPart 1: GMFR of Antibodies for Influenza, as Measured by HAI Assay

Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. Antibody values reported as below LLOQ were replaced by 0.5 \* LLOQ. Values greater than ULOQ were converted to ULOQ. LLOQ = 10 and ULOQ = 640 for Influenza A H1N1 and Influenza A H3N2 antibody, LLOQ = 10 and ULOQ = 320 for Influenza B/Victoria, and LLOQ = 10 and ULOQ = 640 for Influenza B/Yamagata antibody. 95% CI was calculated based on t-distribution of log-transformed values for GMFR, then back transformed to original scale for presentation. PP Set: all randomized participants who received study drug, complied with injection schedule, complied with timings of immunogenicity blood sampling to have a Baseline and at least 1 post-injection assessment at Day 29, had no documented infection of either influenza or SARS-CoV-2 on Day 1 and up to Day 29, had no major dosing error, and had no major protocol deviations or conditions/medications that affected immune response.

Time frame:
Day 29 and Day 181
Reported as:
Geometric mean · ratio
Part 1: GMFR of Antibodies for Influenza, as Measured by HAI Assay
ratioPart 1 Cohort A12: Influenza Vaccine 1Part 1 Cohort A13: Influenza Vaccine 2Part 1 Cohort A11: Investigational Influenza Vaccine 2Part 1 Cohort A8: Investigational Influenza Vaccine 1Part 1 Cohort A2: mRNA-1083.1 Dose Level 2Part 1 Cohort A3: mRNA-1083.1 Dose Level 3Part 1 Cohort A4: mRNA-1083.2 Dose Level 1Part 1 Cohort A5: mRNA-1083.2 Dose Level 2Part 1 Cohort A6: mRNA-1083.2 Dose Level 3Part 1 Cohort A7: mRNA-1083.3Part 1 Cohort B12: Influenza Vaccine 1Part 1 Cohort B11: Investigational Influenza Vaccine 2Part 1 Cohort B8: Investigational Influenza Vaccine 1Part 1 Cohort B1: mRNA-1083.1 Dose Level 1Part 1 Cohort B2: mRNA-1083.1 Dose Level 2Part 1 Cohort B3: mRNA-1083.1 Dose Level 3Part 1 Cohort B4: mRNA-1083.2 Dose Level 1Part 1 Cohort B5: mRNA-1083.2 Dose Level 2Part 1 Cohort B6: mRNA-1083.2 Dose Level 3Part 1 Cohort B7: mRNA-1083.3
Influenza A H1N1 Antibody: Day 291.6 (1.2 to 2.0)1.8 (1.5 to 2.2)2.0 (1.7 to 2.3)2.7 (2.0 to 3.6)1.6 (1.4 to 2.0)2.5 (1.8 to 3.6)1.9 (1.5 to 2.4)2.6 (2.1 to 3.4)2.1 (1.6 to 2.8)2.2 (1.7 to 2.9)2.4 (1.8 to 3.2)2.4 (1.8 to 3.0)2.8 (2.1 to 3.9)2.4 (1.8 to 3.3)2.1 (1.6 to 2.7)2.3 (1.8 to 3.0)3.4 (2.5 to 4.5)2.4 (1.8 to 3.3)2.6 (1.7 to 3.8)2.6 (2.0 to 3.3)
Influenza A H1N1 Antibody: Day 1812.1 (1.6 to 2.8)1.8 (1.3 to 2.4)1.8 (1.4 to 2.2)2.6 (1.6 to 4.2)1.9 (1.5 to 2.3)3.6 (2.6 to 5.0)2.4 (1.8 to 3.2)2.7 (2.0 to 3.7)2.6 (1.9 to 3.7)2.4 (1.9 to 3.2)2.5 (1.8 to 3.4)2.4 (1.9 to 3.1)3.2 (2.6 to 4.1)3.0 (2.2 to 4.1)2.3 (1.8 to 3.1)3.0 (2.1 to 4.3)3.3 (2.5 to 4.3)2.3 (1.7 to 3.1)2.3 (1.6 to 3.3)2.7 (2.0 to 3.6)
Influenza A H3N2 Antibody: Day 291.8 (1.4 to 2.3)2.0 (1.6 to 2.5)2.3 (1.8 to 2.8)3.7 (2.8 to 4.8)2.1 (1.7 to 2.6)3.8 (2.5 to 5.6)2.2 (1.8 to 2.8)2.8 (2.1 to 3.6)2.4 (1.7 to 3.4)3.1 (2.4 to 3.9)2.3 (1.8 to 3.0)2.3 (1.8 to 2.9)2.7 (2.1 to 3.5)2.7 (2.0 to 3.7)2.4 (1.8 to 3.3)2.9 (2.2 to 3.8)3.6 (2.6 to 5.0)2.5 (1.8 to 3.5)2.7 (1.9 to 3.8)3.3 (2.6 to 4.2)
Influenza A H3N2 Antibody: Day 1812.5 (1.8 to 3.4)2.2 (1.6 to 2.9)3.2 (2.4 to 4.2)4.6 (3.1 to 6.8)2.9 (2.3 to 3.5)5.7 (3.4 to 9.5)3.2 (2.4 to 4.4)3.2 (2.3 to 4.3)2.7 (1.9 to 3.9)3.9 (3.0 to 5.0)3.0 (2.3 to 3.9)2.6 (1.9 to 3.4)3.2 (2.3 to 4.5)3.5 (2.5 to 4.8)3.5 (2.4 to 5.0)4.3 (2.9 to 6.4)3.8 (2.6 to 5.8)3.2 (2.3 to 4.3)3.3 (2.4 to 4.4)3.9 (2.8 to 5.5)
Influenza B/Victoria-lineage Antibody: Day 291.8 (1.3 to 2.5)2.2 (1.6 to 2.9)1.9 (1.5 to 2.4)3.3 (2.4 to 4.6)1.9 (1.6 to 2.4)2.5 (1.6 to 3.7)2.0 (1.7 to 2.4)2.9 (2.2 to 3.8)3.3 (2.3 to 4.7)2.5 (1.9 to 3.3)2.4 (1.8 to 3.2)1.9 (1.5 to 2.3)2.7 (2.1 to 3.4)2.1 (1.8 to 2.5)2.5 (1.8 to 3.4)2.6 (1.9 to 3.6)2.2 (1.7 to 2.8)3.1 (2.4 to 3.9)2.7 (2.0 to 3.8)2.4 (1.9 to 3.0)
Influenza B/Victoria-lineage Antibody: Day 1812.9 (2.1 to 4.0)2.4 (1.7 to 3.4)2.1 (1.7 to 2.7)2.9 (2.0 to 4.3)1.9 (1.5 to 2.3)3.2 (2.1 to 5.0)2.3 (1.8 to 2.8)2.4 (1.7 to 3.4)4.0 (2.7 to 5.8)2.9 (2.2 to 3.9)3.1 (2.3 to 4.2)2.2 (1.6 to 2.9)3.4 (2.6 to 4.6)3.1 (2.3 to 4.0)3.6 (2.7 to 4.7)3.0 (1.8 to 5.0)2.5 (1.8 to 3.4)2.6 (2.1 to 3.2)3.1 (2.0 to 4.6)2.9 (2.1 to 4.0)
Influenza B/Yamagata-lineage Antibody: Day 291.5 (1.2 to 1.9)1.9 (1.5 to 2.6)1.6 (1.3 to 1.9)2.0 (1.6 to 2.6)1.4 (1.2 to 1.6)1.6 (1.2 to 2.1)1.5 (1.2 to 1.8)1.8 (1.5 to 2.2)1.7 (1.2 to 2.2)1.6 (1.3 to 1.9)1.9 (1.5 to 2.5)1.8 (1.5 to 2.1)2.1 (1.6 to 2.7)1.9 (1.5 to 2.4)2.0 (1.6 to 2.6)1.8 (1.4 to 2.2)2.1 (1.7 to 2.6)2.1 (1.8 to 2.4)2.4 (1.8 to 3.3)1.9 (1.5 to 2.4)
Influenza B/Yamagata-lineage Antibody: Day 1811.9 (1.3 to 2.7)1.8 (1.1 to 3.0)1.3 (0.8 to 2.2)2.0 (1.3 to 3.0)1.3 (1.0 to 1.6)1.7 (1.0 to 2.9)1.2 (0.9 to 1.7)1.6 (1.0 to 2.7)2.0 (1.3 to 3.3)1.4 (1.0 to 1.9)1.1 (0.8 to 1.4)0.9 (0.7 to 1.3)1.4 (1.0 to 1.9)1.3 (0.9 to 1.8)1.4 (1.0 to 1.9)0.9 (0.7 to 1.3)1.5 (1.1 to 2.1)1.1 (0.8 to 1.6)1.2 (0.9 to 1.8)1.1 (0.8 to 1.5)
SecondaryPart 1: GMFR of Antibodies for SARS-CoV-2, as Measured by PsVNA

SARS-CoV-2 strain included BA.4/5 and D614G antibody. Antibody values reported as below LLOQ were replaced by 0.5 \* LLOQ. Values greater than ULOQ were converted to ULOQ. LLOQ = 53 and ULOQ = 71376 for SARS-CoV-2 BA.4/5 antibody and LLOQ = 74.1 and ULOQ = 184317 for SARS-CoV-2 D614G antibody. 95% CI was calculated based on t-distribution of log-transformed values for GMFR, then back transformed to original scale for presentation. PP Set: all randomized participants who received study drug, complied with injection schedule, complied with timings of immunogenicity blood sampling to have a Baseline and at least 1 post-injection assessment at Day 29, had no documented infection of either influenza or SARS-CoV-2 on Day 1 and up to Day 29, had no major dosing error, and had no major protocol deviations or conditions/medications that affected immune response.

Time frame:
Day 29 and Day 181
Reported as:
Geometric mean · ratio
Part 1: GMFR of Antibodies for SARS-CoV-2, as Measured by PsVNA
ratioPart 1 Cohort A10: COVID-19 Vaccine 1Part 1 Cohort A9: Investigational COVID-19 Vaccine 1Part 1 Cohort A2: mRNA-1083.1 Dose Level 2Part 1 Cohort A3: mRNA-1083.1 Dose Level 3Part 1 Cohort A4: mRNA-1083.2 Dose Level 1Part 1 Cohort A5: mRNA-1083.2 Dose Level 2Part 1 Cohort A6: mRNA-1083.2 Dose Level 3Part 1 Cohort A7: mRNA-1083.3Part 1 Cohort B10: COVID-19 Vaccine 1Part 1 Cohort B9: Investigational COVID-19 Vaccine 1Part 1 Cohort B1: mRNA-1083.1 Dose Level 1Part 1 Cohort B2: mRNA-1083.1 Dose Level 2Part 1 Cohort B3: mRNA-1083.1 Dose Level 3Part 1 Cohort B4: mRNA-1083.2 Dose Level 1Part 1 Cohort B5: mRNA-1083.2 Dose Level 2Part 1 Cohort B6: mRNA-1083.2 Dose Level 3Part 1 Cohort B7: mRNA-1083.3
SARS-CoV-2 BA.4/5 Antibody: Day 297.3 (5.0 to 10.9)10.0 (7.0 to 14.2)7.5 (5.0 to 11.2)9.6 (6.5 to 14.4)5.7 (4.1 to 7.9)6.8 (4.8 to 9.7)5.6 (3.7 to 8.5)4.7 (3.3 to 6.7)6.9 (4.7 to 10.0)10.9 (7.5 to 15.9)6.1 (4.2 to 9.0)6.9 (5.1 to 9.5)7.4 (4.9 to 11.1)7.3 (5.1 to 10.5)8.4 (5.9 to 11.8)10.3 (6.7 to 16.0)6.9 (4.6 to 10.4)
SARS-CoV-2 BA.4/5 Antibody: Day 1812.5 (1.7 to 3.6)4.1 (2.7 to 6.3)3.2 (2.1 to 5.0)4.4 (2.3 to 8.4)2.6 (1.8 to 3.8)2.4 (1.6 to 3.8)1.9 (1.1 to 3.2)1.7 (1.1 to 2.5)3.5 (2.2 to 5.5)4.4 (3.1 to 6.4)2.8 (1.9 to 4.1)2.7 (1.9 to 3.9)2.7 (1.5 to 4.6)3.1 (2.1 to 4.6)3.5 (2.4 to 5.0)3.6 (2.4 to 5.3)2.9 (2.0 to 4.3)
SARS-CoV-2 D614G Antibody: Day 294.8 (3.6 to 6.5)5.6 (4.1 to 7.7)4.2 (2.9 to 6.0)4.0 (2.9 to 5.6)2.5 (1.9 to 3.4)4.1 (2.9 to 5.7)3.1 (2.2 to 4.2)3.0 (2.4 to 3.7)4.5 (3.4 to 6.2)5.8 (4.0 to 8.5)3.2 (2.4 to 4.2)3.6 (2.7 to 4.7)4.2 (3.1 to 5.7)4.3 (3.1 to 5.9)3.8 (2.9 to 5.1)5.3 (3.8 to 7.3)4.5 (3.2 to 6.3)
SARS-CoV-2 D614G Antibody: Day 1811.7 (1.3 to 2.3)2.5 (1.7 to 3.8)1.7 (1.1 to 2.4)1.6 (1.0 to 2.8)1.2 (0.9 to 1.6)1.7 (1.2 to 2.4)1.6 (1.1 to 2.4)1.4 (1.1 to 1.7)2.0 (1.3 to 2.9)2.5 (1.8 to 3.5)1.5 (1.2 to 1.8)1.5 (1.1 to 2.1)1.4 (1.1 to 1.9)1.7 (1.3 to 2.3)1.4 (1.0 to 1.9)1.5 (1.2 to 2.0)1.7 (1.2 to 2.4)
SecondaryPart 1: Influenza: Percentage of Participants With Seroconversion, as Measured by HAI Assay

Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. Seroconversion was defined as a pre-vaccination HAI titer \< 1:10 and a post-vaccination HAI titer ≥1:40 or a pre-vaccination HAI titer ≥1:10 and a minimum 4-fold rise in post vaccination HAI antibody titer. PP Set: all randomized participants who received study drug, complied with injection schedule, complied with timings of immunogenicity blood sampling to have a Baseline and at least 1 post-injection assessment at Day 29, had no documented infection of either influenza or SARS-CoV-2 on Day 1 and up to Day 29, had no major dosing error, and had no major protocol deviations or conditions/medications that affected immune response.

Time frame:
Baseline (Day 1) to Day 29, and Day 181
Reported as:
Number · percentage of participants
Part 1: Influenza: Percentage of Participants With Seroconversion, as Measured by HAI Assay
percentage of participantsPart 1 Cohort A12: Influenza Vaccine 1Part 1 Cohort A13: Influenza Vaccine 2Part 1 Cohort A11: Investigational Influenza Vaccine 2Part 1 Cohort A8: Investigational Influenza Vaccine 1Part 1 Cohort A2: mRNA-1083.1 Dose Level 2Part 1 Cohort A3: mRNA-1083.1 Dose Level 3Part 1 Cohort A4: mRNA-1083.2 Dose Level 1Part 1 Cohort A5: mRNA-1083.2 Dose Level 2Part 1 Cohort A6: mRNA-1083.2 Dose Level 3Part 1 Cohort A7: mRNA-1083.3Part 1 Cohort B12: Influenza Vaccine 1Part 1 Cohort B11: Investigational Influenza Vaccine 2Part 1 Cohort B8: Investigational Influenza Vaccine 1Part 1 Cohort B1: mRNA-1083.1 Dose Level 1Part 1 Cohort B2: mRNA-1083.1 Dose Level 2Part 1 Cohort B3: mRNA-1083.1 Dose Level 3Part 1 Cohort B4: mRNA-1083.2 Dose Level 1Part 1 Cohort B5: mRNA-1083.2 Dose Level 2Part 1 Cohort B6: mRNA-1083.2 Dose Level 3Part 1 Cohort B7: mRNA-1083.3
Influenza A H1N1 Antibody: Day 2911.8 (4.4 to 23.9)14.0 (5.8 to 26.7)18.4 (8.8 to 32.0)28.9 (16.4 to 44.3)12.0 (4.5 to 24.3)33.3 (17.3 to 52.8)20.8 (10.8 to 34.1)34.0 (20.9 to 49.3)19.4 (7.5 to 37.5)18.0 (8.6 to 31.4)30.0 (17.9 to 44.6)27.7 (15.6 to 42.6)36.5 (23.6 to 51.0)30.0 (17.9 to 44.6)20.8 (10.8 to 34.1)19.4 (8.2 to 36.0)48.0 (33.7 to 62.6)30.8 (18.7 to 45.1)29.7 (15.9 to 47.0)37.3 (24.1 to 51.9)
Influenza A H1N1 Antibody: Day 18128.2 (15.0 to 44.9)16.7 (6.4 to 32.8)16.1 (5.5 to 33.7)30.6 (16.3 to 48.1)23.3 (11.8 to 38.6)50.0 (28.2 to 71.8)27.3 (15.0 to 42.8)32.4 (18.0 to 49.8)36.0 (18.0 to 57.5)21.4 (10.3 to 36.8)31.1 (18.2 to 46.6)33.3 (19.1 to 50.2)40.9 (26.3 to 56.8)40.9 (26.3 to 56.8)38.6 (24.4 to 54.5)36.0 (18.0 to 57.5)44.2 (29.1 to 60.1)29.2 (17.0 to 44.1)29.6 (13.8 to 50.2)37.8 (23.8 to 53.5)
Influenza A H3N2 Antibody: Day 2915.7 (7.0 to 28.6)22.0 (11.5 to 36.0)22.4 (11.8 to 36.6)55.6 (40.0 to 70.4)26.0 (14.6 to 40.3)43.3 (25.5 to 62.6)22.6 (12.3 to 36.2)38.0 (24.7 to 52.8)25.8 (11.9 to 44.6)44.9 (30.7 to 59.8)32.0 (19.5 to 46.7)31.9 (19.1 to 47.1)40.4 (27.0 to 54.9)34.0 (21.2 to 48.8)24.5 (13.8 to 38.3)44.4 (27.9 to 61.9)44.0 (30.0 to 58.7)38.5 (25.3 to 53.0)35.1 (20.2 to 52.5)34.0 (21.2 to 48.8)
Influenza A H3N2 Antibody: Day 18133.3 (19.1 to 50.2)25.0 (12.1 to 42.2)45.2 (27.3 to 64.0)61.1 (43.5 to 76.9)39.5 (25.0 to 55.6)63.6 (40.7 to 82.8)43.2 (28.3 to 59.0)50.0 (33.4 to 66.6)32.0 (14.9 to 53.5)51.2 (35.1 to 67.1)44.4 (29.6 to 60.0)30.8 (17.0 to 47.6)47.7 (32.5 to 63.3)38.6 (24.4 to 54.5)38.6 (24.4 to 54.5)44.0 (24.4 to 65.1)46.5 (31.2 to 62.3)52.1 (37.2 to 66.7)40.7 (22.4 to 61.2)52.3 (36.7 to 67.5)
Influenza B/Victoria-lineage Antibody: Day 2921.6 (11.3 to 35.3)18.0 (8.6 to 31.4)22.4 (11.8 to 36.6)48.8 (33.3 to 64.5)16.0 (7.2 to 29.1)23.3 (9.9 to 42.3)24.5 (13.8 to 38.3)36.2 (22.7 to 51.5)41.9 (24.5 to 60.9)28.0 (16.2 to 42.5)34.0 (21.2 to 48.8)13.0 (4.9 to 26.3)38.5 (25.3 to 53.0)16.0 (7.2 to 29.1)34.0 (21.5 to 48.3)38.9 (23.1 to 56.5)28.0 (16.2 to 42.5)38.5 (25.3 to 53.0)38.9 (23.1 to 56.5)28.0 (16.2 to 42.5)
Influenza B/Victoria-lineage Antibody: Day 18135.9 (21.2 to 52.8)27.8 (14.2 to 45.2)25.8 (11.9 to 44.6)37.1 (21.5 to 55.1)18.6 (8.4 to 33.4)50.0 (28.2 to 71.8)20.5 (9.8 to 35.3)32.4 (18.0 to 49.8)60.0 (38.7 to 78.9)33.3 (19.6 to 49.5)48.9 (33.7 to 64.2)31.6 (17.5 to 48.7)43.2 (28.3 to 59.0)47.7 (32.5 to 63.3)45.5 (30.4 to 61.2)32.0 (14.9 to 53.5)32.6 (19.1 to 48.5)35.4 (22.2 to 50.5)48.1 (28.7 to 68.1)45.5 (30.4 to 61.2)
Influenza B/Yamagata-lineage Antibody: Day 299.8 (3.3 to 21.4)18.0 (8.6 to 31.4)12.2 (4.6 to 24.8)28.9 (16.4 to 44.3)2.0 (0.1 to 10.6)13.3 (3.8 to 30.7)7.5 (2.1 to 18.2)16.7 (7.5 to 30.2)16.1 (5.5 to 33.7)6.0 (1.3 to 16.5)24.0 (13.1 to 38.2)12.8 (4.8 to 25.7)23.1 (12.5 to 36.8)20.0 (10.0 to 33.7)21.2 (11.1 to 34.7)19.4 (8.2 to 36.0)20.0 (10.0 to 33.7)17.3 (8.2 to 30.3)32.4 (18.0 to 49.8)16.0 (7.2 to 29.1)
Influenza B/Yamagata-lineage Antibody: Day 18128.2 (15.0 to 44.9)33.3 (18.6 to 51.0)19.4 (7.5 to 37.5)36.1 (20.8 to 53.8)9.3 (2.6 to 22.1)27.3 (10.7 to 50.2)15.9 (6.6 to 30.1)23.7 (11.4 to 40.2)29.2 (12.6 to 51.1)19.0 (8.6 to 34.1)8.9 (2.5 to 21.2)12.8 (4.3 to 27.4)18.2 (8.2 to 32.7)20.9 (10.0 to 36.0)15.9 (6.6 to 30.1)0 (0.0 to 13.7)16.3 (6.8 to 30.7)14.6 (6.1 to 27.8)14.8 (4.2 to 33.7)11.4 (3.8 to 24.6)
SecondaryPart 1: SARS-CoV-2: Percentage of Participants With Seroresponse, as Measured by PsVNA

SARS-CoV-2 strain included BA.4/5 and D614G antibody. Seroresponse was defined as an increase from below the LLOQ to ≥4 x LLOQ if baseline nAb level was \<LLOQ, or ≥4 fold rise if baseline nAb level was ≥LLOQ. PP Set: all randomized participants who received study drug, complied with injection schedule, complied with timings of immunogenicity blood sampling to have a Baseline and at least 1 post-injection assessment at Day 29, had no documented infection of either influenza or SARS-CoV-2 on Day 1 and up to Day 29, had no major dosing error, and had no major protocol deviations or conditions/medications that affected immune response.

Time frame:
Baseline (Day 1) to Day 29, and Day 181
Reported as:
Number · percentage of participants
Part 1: SARS-CoV-2: Percentage of Participants With Seroresponse, as Measured by PsVNA
percentage of participantsPart 1 Cohort A10: COVID-19 Vaccine 1Part 1 Cohort A9: Investigational COVID-19 Vaccine 1Part 1 Cohort A2: mRNA-1083.1 Dose Level 2Part 1 Cohort A3: mRNA-1083.1 Dose Level 3Part 1 Cohort A4: mRNA-1083.2 Dose Level 1Part 1 Cohort A5: mRNA-1083.2 Dose Level 2Part 1 Cohort A6: mRNA-1083.2 Dose Level 3Part 1 Cohort A7: mRNA-1083.3Part 1 Cohort B10: COVID-19 Vaccine 1Part 1 Cohort B9: Investigational COVID-19 Vaccine 1Part 1 Cohort B1: mRNA-1083.1 Dose Level 1Part 1 Cohort B2: mRNA-1083.1 Dose Level 2Part 1 Cohort B3: mRNA-1083.1 Dose Level 3Part 1 Cohort B4: mRNA-1083.2 Dose Level 1Part 1 Cohort B5: mRNA-1083.2 Dose Level 2Part 1 Cohort B6: mRNA-1083.2 Dose Level 3Part 1 Cohort B7: mRNA-1083.3
SARS-CoV-2 BA.4/5 Antibody: Day 2962.7 (48.1 to 75.9)69.4 (54.6 to 81.7)68.0 (53.3 to 80.5)75.9 (56.5 to 89.7)56.9 (45.1 to 73.0)62.7 (48.1 to 75.9)58.1 (39.1 to 75.5)44.0 (30.0 to 58.7)60.0 (45.2 to 73.6)76.5 (62.5 to 87.2)51.0 (36.6 to 65.2)62.3 (47.9 to 75.5)58.3 (40.8 to 74.5)60.0 (45.2 to 73.6)65.4 (50.9 to 78.0)68.4 (51.3 to 82.5)68.0 (53.3 to 80.5)
SARS-CoV-2 BA.4/5 Antibody: Day 18137.8 (23.8 to 53.5)44.7 (28.6 to 61.7)41.9 (27.0 to 57.9)50.0 (28.2 to 71.8)41.9 (27.0 to 57.9)28.2 (15.0 to 44.9)20.0 (6.8 to 40.7)16.7 (7.0 to 31.4)40.9 (26.3 to 56.8)53.2 (38.1 to 67.9)29.5 (16.8 to 45.2)31.8 (18.6 to 47.6)32.0 (14.9 to 53.5)34.9 (21.0 to 50.9)39.6 (25.8 to 54.7)42.9 (24.5 to 62.8)35.6 (21.9 to 51.2)
SARS-CoV-2 D614G Antibody: Day 2943.1 (29.3 to 57.8)57.1 (42.2 to 71.2)37.5 (24.0 to 52.6)56.7 (37.4 to 74.5)21.2 (11.1 to 34.7)43.1 (29.3 to 57.8)25.8 (11.9 to 44.6)32.0 (19.5 to 46.7)42.0 (28.2 to 56.8)50.9 (36.8 to 64.9)33.3 (20.8 to 47.9)39.6 (26.5 to 54.0)41.7 (25.5 to 59.2)42.0 (28.2 to 56.8)48.1 (34.0 to 62.4)57.9 (40.8 to 73.7)42.0 (28.2 to 56.8)
SARS-CoV-2 D614G Antibody: Day 18117.8 (8.0 to 32.1)31.6 (17.5 to 48.7)18.6 (8.4 to 33.4)18.2 (5.2 to 40.3)7.0 (1.5 to 19.1)17.9 (7.5 to 33.5)12.0 (2.5 to 31.2)7.1 (1.5 to 19.5)22.7 (11.5 to 37.8)34.0 (20.9 to 49.3)9.1 (2.5 to 21.7)11.4 (3.8 to 24.6)8.0 (1.0 to 26.0)23.3 (11.8 to 38.6)12.5 (4.7 to 25.2)3.6 (0.1 to 18.3)15.9 (6.6 to 30.1)
SecondaryPart 2: GMT of Antibodies for Influenza, as Measured by HAI Assay

Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were converted to the ULOQ. LLOQ = 10 and ULOQ = 3620 for Influenza A H1N1 antibody, LLOQ = 10 and ULOQ = 5120 for Influenza A H3N2 antibody, LLOQ = 10 and ULOQ = 1356 for Influenza B/Victoria-lineage antibody, and LLOQ = 10 and ULOQ = 1280 for Influenza B/Yamagata-lineage antibody. 95% CI was calculated based on the t-distribution of the log-transformed values for GM titer, then back transformed to the original scale for presentation. Arms based on the applicable vaccine for this Outcome Measure.

Time frame:
Baseline (Day 1), Day 181
Reported as:
Geometric mean · titer
Part 2: GMT of Antibodies for Influenza, as Measured by HAI Assay
titerPart 2: Influenza Vaccine 1Part 2: Investigational Influenza Vaccine 1 Dose Level 1Part 2: Investigational Influenza Vaccine 1 Dose Level 2Part 2: mRNA-1083 Composition 1 Dose Level 1Part 2: mRNA-1083 Composition 1 Dose Level 2Part 2: mRNA-1083 Composition 1 Dose Level 3Part 2: mRNA-1083 Composition 1 Dose Level 4Part 2: mRNA-1083 Composition 2 Dose Level 1Part 2: mRNA-1083 Composition 2 Dose Level 2Part 2: mRNA-1083 Composition 2 Dose Level 3Part 2: mRNA-1083 Composition 2 Dose Level 4
Influenza A H1N1 Antibody: Day 130.4 (20.3 to 45.4)30.1 (20.7 to 43.9)35.1 (24.0 to 51.3)41.8 (31.5 to 64.1)44.9 (31.5 to 64.1)40.6 (29.6 to 55.7)49.9 (33.3 to 74.8)45.5 (32.6 to 63.5)32.7 (22.9 to 46.8)31.4 (21.0 to 46.9)37.1 (26.7 to 51.6)
Influenza A H1N1 Antibody: Day 18181.6 (57.6 to 115.8)91.3 (65.4 to 127.6)108.4 (74.6 to 157.5)95.1 (65.9 to 137.1)93.1 (63.1 to 137.4)119.9 (87.7 to 163.9)111.9 (72.1 to 173.6)76.4 (52.4 to 111.4)108.4 (78.2 to 150.2)82.8 (60.6 to 113.2)101.5 (73.1 to 141.1)
Influenza A H3N2 Antibody: Day 128.8 (21.3 to 38.8)36.5 (24.3 to 54.7)46.0 (31.9 to 66.3)37.2 (27.8 to 49.8)36.8 (28.1 to 48.3)46.4 (33.2 to 64.8)39.6 (28.9 to 54.4)36.6 (26.8 to 50.0)35.2 (25.7 to 48.3)42.1 (30.5 to 58.3)30.2 (22.9 to 39.7)
Influenza A H3N2 Antibody: Day 18150.9 (37.1 to 69.8)65.2 (45.5 to 93.5)100.7 (72.9 to 139.2)64.1 (46.3 to 88.8)52.6 (38.2 to 72.5)89.8 (62.2 to 129.6)61.7 (43.7 to 87.0)49.3 (35.6 to 68.3)63.0 (45.5 to 87.3)82.9 (57.6 to 119.2)52.4 (37.7 to 72.9)
Influenza B/Victoria-lineage Antibody: Day 149.8 (38.6 to 64.2)41.0 (31.7 to 53.0)60.4 (49.9 to 73.1)52.6 (40.7 to 68.0)64.6 (49.0 to 85.0)62.3 (49.1 to 79.0)50.8 (39.0 to 66.2)66.1 (49.1 to 89.0)53.6 (41.1 to 69.8)49.3 (38.3 to 63.5)48.7 (37.4 to 63.5)
Influenza B/Victoria-lineage Antibody: Day 18154.2 (39.7 to 74.1)55.4 (42.4 to 72.5)64.9 (47.9 to 87.9)56.5 (43.0 to 74.3)73.0 (54.6 to 97.4)69.9 (51.9 to 94.0)71.0 (53.2 to 94.8)62.5 (46.7 to 83.7)56.0 (44.5 to 70.4)62.0 (48.4 to 79.4)56.6 (44.8 to 71.4)
Influenza B/Yamagata-lineage Antibody: Day 180.8 (60.1 to 108.5)54.5 (40.8 to 72.9)84.7 (63.7 to 112.6)63.0 (47.2 to 83.9)70.1 (54.7 to 89.8)69.7 (53.6 to 90.5)69.4 (52.1 to 92.3)72.1 (53.8 to 96.6)73.6 (52.3 to 103.6)67.6 (49.9 to 91.5)63.0 (49.6 to 80.0)
Influenza B/Yamagata-lineage Antibody: Day 181110.8 (82.9 to 148.0)92.3 (71.4 to 119.2)108.5 (78.7 to 149.4)68.5 (50.7 to 92.7)70.8 (54.7 to 91.6)80.7 (60.9 to 107.0)82.6 (59.1 to 115.5)60.8 (45.1 to 82.1)73.3 (54.0 to 99.6)84.7 (63.4 to 113.3)63.0 (46.1 to 86.1)
SecondaryPart 2: GM Concentration of Antibodies for SARS-CoV-2, as Measured by PsVNA

SARS-CoV-2 strain included Omicron XBB.1.5 antibody. Antibody values reported as below the LLOQ are replaced by 0.5 \* LLOQ. Values greater than the ULOQ are converted to the ULOQ. LLOQ = 38 and ULOQ = 6960 arbitrary units (AU)/milliliter (mL) for SARS-CoV-2 Omicron XBB.1.5 antibody. 95% CI was calculated based on the t-distribution of the log-transformed values for GM concentration, then back transformed to the original scale for presentation. Arms based on the applicable vaccine for this Outcome Measure.

Time frame:
Baseline (Day 1), Day 181
Reported as:
Geometric mean · AU/mL
Part 2: GM Concentration of Antibodies for SARS-CoV-2, as Measured by PsVNA
AU/mLPart 2: COVID-19 Vaccine 2Part 2: Investigational COVID-19 Vaccine 2Part 2: mRNA-1083 Composition 1 Dose Level 1Part 2: mRNA-1083 Composition 1 Dose Level 2Part 2: mRNA-1083 Composition 1 Dose Level 3Part 2: mRNA-1083 Composition 1 Dose Level 4Part 2: mRNA-1083 Composition 2 Dose Level 1Part 2: mRNA-1083 Composition 2 Dose Level 2Part 2: mRNA-1083 Composition 2 Dose Level 3Part 2: mRNA-1083 Composition 2 Dose Level 4
SARS-CoV-2 Omicron XBB.1.5 Antibody: Day 1292.2 (197.1 to 433.1)214.1 (145.3 to 315.4)128.8 (82.4 to 201.3)168.1 (110.3 to 256.1)198.5 (121.2 to 325.1)307.8 (194.8 to 486.4)151.5 (96.2 to 238.6)212.0 (140.8 to 319.2)127.6 (81.4 to 200.1)136.2 (92.0 to 201.7)
SARS-CoV-2 Omicron XBB.1.5 Antibody: Day 181906.7 (678.5 to 1211.6)998.7 (640.6 to 1557.2)377.8 (258.0 to 553.4)562.2 (364.2 to 867.8)629.8 (419.3 to 946.0)809.5 (555.1 to 1180.3)349.0 (225.7 to 539.8)642.9 (445.3 to 928.2)682.7 (429.1 to 1086.2)472 (307.2 to 725.3)
SecondaryPart 2: GMFR of Antibodies for Influenza, as Measured by HAI Assay

Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. Antibody values reported as below LLOQ replaced by 0.5 \* LLOQ. Values greater than ULOQ converted to ULOQ. LLOQ= 10, ULOQ= 3620 for Influenza A H1N1, LLOQ= 10, ULOQ= 5120 for Influenza A H3N2, LLOQ= 10, ULOQ= 1356 for Influenza B/Victoria-lineage, and LLOQ= 10, ULOQ= 1280 for Influenza B/Yamagata-lineage. 95% CI was calculated based on t-distribution of log-transformed values for GMFR, then back transformed to original scale for presentation. PP Set: all randomized participants who received study drug, complied with injection schedule, complied with timings of immunogenicity blood sampling to have a Baseline and at least 1 post-injection assessment at Day 29, had no documented infection of either influenza or SARS-CoV-2 on Day 1 and up to Day 29, had no major dosing error, and had no major protocol deviations or conditions/medications that affected immune response.

Time frame:
Day 181
Reported as:
Geometric mean · ratio
Part 2: GMFR of Antibodies for Influenza, as Measured by HAI Assay
ratioPart 2: Influenza Vaccine 1Part 2: Investigational Influenza Vaccine 1 Dose Level 1Part 2: Investigational Influenza Vaccine 1 Dose Level 2Part 2: mRNA-1083 Composition 1 Dose Level 1Part 2: mRNA-1083 Composition 1 Dose Level 2Part 2: mRNA-1083 Composition 1 Dose Level 3Part 2: mRNA-1083 Composition 1 Dose Level 4Part 2: mRNA-1083 Composition 2 Dose Level 1Part 2: mRNA-1083 Composition 2 Dose Level 2Part 2: mRNA-1083 Composition 2 Dose Level 3Part 2: mRNA-1083 Composition 2 Dose Level 4
Influenza A H1N1 Antibody2.9 (2.0 to 4.2)3.2 (2.3 to 4.4)3.1 (2.2 to 4.3)2.3 (1.8 to 2.8)2.1 (1.5 to 2.9)2.9 (2.2 to 3.9)2.3 (1.7 to 3.2)1.7 (1.2 to 2.4)3.7 (2.4 to 5.6)2.8 (2.0 to 4.1)3.0 (2.2 to 4.1)
Influenza A H3N2 Antibody2.0 (1.5 to 2.6)1.9 (1.5 to 2.6)2.1 (1.5 to 2.8)1.7 (1.3 to 2.2)1.4 (1.0 to 1.8)2.0 (1.6 to 2.6)1.4 (1.0 to 2.0)1.4 (1.1 to 1.7)2.0 (1.6 to 2.6)1.8 (1.4 to 2.5)1.8 (1.4 to 2.5)
Influenza B/Victoria-lineage Antibody1.2 (0.9 to 1.6)1.4 (1.1 to 1.9)1.1 (0.9 to 1.5)1.1 (0.8 to 1.4)1.1 (0.8 to 1.5)1.2 (0.9 to 1.5)1.4 (1.1 to 1.8)1.0 (0.7 to 1.3)1.2 (0.9 to 1.5)1.3 (1.0 to 1.7)1.2 (0.9 to 1.5)
Influenza B/Yamagata-lineage Antibody1.3 (1.1 to 1.6)1.6 (1.3 to 1.9)1.3 (1.0 to 1.6)1.1 (0.9 to 1.4)1.0 (0.8 to 1.3)1.2 (1.0 to 1.4)1.2 (1.0 to 1.6)0.9 (0.7 to 1.0)1.2 (0.9 to 1.6)1.2 (1.0 to 1.6)1.1 (0.8 to 1.3)
SecondaryPart 2: GMFR of Antibodies for SARS-CoV-2, as Measured by PsVNA

SARS-CoV-2 strain included Omicron XBB.1.5 antibody. Antibody values reported as below the LLOQ are replaced by 0.5 \* LLOQ. Values greater than the ULOQ are converted to the ULOQ. LLOQ = 38 and ULOQ = 6960 AU/mL for SARS-CoV-2 Omicron XBB.1.5 antibody. 95% CI was calculated based on the t-distribution of the log-transformed values for GMFR values, then back transformed to the original scale for presentation. PP Set: all randomized participants who received study drug, complied with injection schedule, complied with timings of immunogenicity blood sampling to have a Baseline and at least 1 post-injection assessment at Day 29, had no documented infection of either influenza or SARS-CoV-2 on Day 1 and up to Day 29, had no major dosing error, and had no major protocol deviations or conditions/medications that affected immune response.

Time frame:
Day 181
Reported as:
Geometric mean · ratio
Part 2: GMFR of Antibodies for SARS-CoV-2, as Measured by PsVNA
ratioPart 2: COVID-19 Vaccine 2Part 2: Investigational COVID-19 Vaccine 2Part 2: mRNA-1083 Composition 1 Dose Level 1Part 2: mRNA-1083 Composition 1 Dose Level 2Part 2: mRNA-1083 Composition 1 Dose Level 3Part 2: mRNA-1083 Composition 1 Dose Level 4Part 2: mRNA-1083 Composition 2 Dose Level 1Part 2: mRNA-1083 Composition 2 Dose Level 2Part 2: mRNA-1083 Composition 2 Dose Level 3Part 2: mRNA-1083 Composition 2 Dose Level 4
Part 2: GMFR of Antibodies for SARS-CoV-2, as Measured by PsVNA3.3 (2.2 to 4.8)4.5 (2.7 to 7.7)2.8 (1.8 to 4.5)3.7 (2.2 to 6.2)3.4 (2.3 to 5.1)2.3 (1.5 to 3.5)2.5 (1.6 to 4.0)2.9 (1.9 to 4.5)4.7 (2.7 to 8.1)3.9 (2.8 to 5.5)
SecondaryPart 2: Influenza: Percentage of Participants With Seroconversion, as Measured by HAI Assay

Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria-lineage and Yamagata-lineage. Seroconversion was defined as a pre-vaccination HAI titer \<1:10 and a post-vaccination HAI titer ≥1:40 or a pre-vaccination HAI titer ≥1:10 and a minimum 4-fold rise in post-vaccination HAI antibody titer. PP Set included all randomized participants who received the study intervention, complied with the injection schedule, complied with the timings of immunogenicity blood sampling to have a Baseline and at least 1 post-injection assessment at Day 29, had no documented infection of either influenza or SARS-CoV-2 on Day 1 and up to Day 29, had no major dosing error, and had no major protocol deviations or conditions/medications that affected the immune response.

Time frame:
Baseline (Day 1) to Day 181
Reported as:
Number · percentage of participants
Part 2: Influenza: Percentage of Participants With Seroconversion, as Measured by HAI Assay
percentage of participantsPart 2: Influenza Vaccine 1Part 2: Investigational Influenza Vaccine 1 Dose Level 1Part 2: Investigational Influenza Vaccine 1 Dose Level 2Part 2: mRNA-1083 Composition 1 Dose Level 1Part 2: mRNA-1083 Composition 1 Dose Level 2Part 2: mRNA-1083 Composition 1 Dose Level 3Part 2: mRNA-1083 Composition 1 Dose Level 4Part 2: mRNA-1083 Composition 2 Dose Level 1Part 2: mRNA-1083 Composition 2 Dose Level 2Part 2: mRNA-1083 Composition 2 Dose Level 3Part 2: mRNA-1083 Composition 2 Dose Level 4
Influenza A H1N1 Antibody45.5 (28.1 to 63.6)50.0 (32.4 to 67.6)36.4 (20.4 to 54.9)22.2 (10.1 to 39.2)23.5 (10.7 to 41.2)36.1 (20.8 to 53.8)25.0 (11.5 to 43.4)26.3 (13.4 to 43.1)40.6 (23.7 to 59.4)40.0 (22.7 to 59.4)43.8 (26.4 to 62.3)
Influenza A H3N2 Antibody30.3 (15.6 to 48.7)29.4 (15.1 to 47.5)24.2 (11.1 to 42.3)19.4 (8.2 to 36.0)11.8 (3.3 to 27.5)25.0 (12.1 to 42.2)15.6 (5.3 to 32.8)10.5 (2.9 to 24.8)34.4 (18.6 to 53.2)26.7 (12.3 to 45.9)28.1 (13.7 to 46.7)
Influenza B/Victoria-lineage Antibody12.1 (3.4 to 28.2)8.8 (1.9 to 23.7)9.1 (1.9 to 24.3)5.6 (0.7 to 18.7)8.8 (1.9 to 23.7)5.6 (0.7 to 18.7)9.4 (2.0 to 25.0)10.5 (2.9 to 24.8)12.5 (3.5 to 29.0)10.0 (2.1 to 26.5)6.3 (0.8 to 20.8)
Influenza B/Yamagata-lineage Antibody9.1 (1.9 to 24.3)8.8 (1.9 to 23.7)6.1 (0.7 to 20.2)5.6 (0.7 to 18.7)2.9 (0.1 to 15.3)2.8 (0.1 to 14.5)9.4 (2.0 to 25.0)2.6 (0.1 to 13.8)6.3 (0.8 to 20.8)6.7 (0.8 to 20.8)0 (0.0 to 10.9)
SecondaryPart 2: SARS-CoV-2: Percentage of Participants With Seroresponse, as Measured by PsVNA

SARS-CoV-2 strain included Omicron XBB.1.5 antibody. Seroresponse was defined as an increase from below the LLOQ to ≥4 \* LLOQ if Baseline nAb level was \< LLOQ, or ≥4-fold rise if Baseline nAb level was ≥ LLOQ. PP Set included all randomized participants who received the study intervention, complied with the injection schedule, complied with the timings of immunogenicity blood sampling to have a Baseline and at least 1 post-injection assessment at Day 29, had no documented infection of either influenza or SARS-CoV-2 on Day 1 and up to Day 29, had no major dosing error, and had no major protocol deviations or conditions/medications that affected the immune response.

Time frame:
Baseline (Day 1) to Day 181
Reported as:
Number · percentage of participants
Part 2: SARS-CoV-2: Percentage of Participants With Seroresponse, as Measured by PsVNA
percentage of participantsPart 2: COVID-19 Vaccine 2Part 2: Investigational COVID-19 Vaccine 2Part 2: mRNA-1083 Composition 1 Dose Level 1Part 2: mRNA-1083 Composition 1 Dose Level 2Part 2: mRNA-1083 Composition 1 Dose Level 3Part 2: mRNA-1083 Composition 1 Dose Level 4Part 2: mRNA-1083 Composition 2 Dose Level 1Part 2: mRNA-1083 Composition 2 Dose Level 2Part 2: mRNA-1083 Composition 2 Dose Level 3Part 2: mRNA-1083 Composition 2 Dose Level 4
Part 2: SARS-CoV-2: Percentage of Participants With Seroresponse, as Measured by PsVNA40.5 (24.8 to 57.9)43.3 (25.5 to 62.6)36.1 (20.8 to 53.8)32.4 (17.4 to 50.5)37.1 (21.5 to 55.1)25.0 (11.5 to 43.4)31.6 (17.5 to 48.7)28.1 (13.7 to 46.7)50.0 (31.3 to 68.7)50.0 (31.9 to 68.1)

Adverse events

Collected over All-cause mortality, SAEs, AESIs, MAAEs, and AEs leading to study discontinuation were collected up to Day 181. Other (non-serious) adverse events were collected from the time of injection through 28 days after the injection, unless they met the criteria for AESIs, MAAEs, or AEs led to study discontinuation.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1 Cohort A12: Influenza Vaccine 10/54 (0%)2/54 (3.7%)1/54 (1.9%)
Part 1 Cohort A13: Influenza Vaccine 20/53 (0%)2/53 (3.8%)3/53 (5.7%)
Part 1 Cohort A11: Investigational Influenza Vaccine 20/54 (0%)1/54 (1.9%)4/54 (7.4%)
Part 1 Cohort A8: Investigational Influenza Vaccine 10/53 (0%)1/51 (2%)3/51 (5.9%)
Part 1 Cohort A10: COVID-19 Vaccine 10/54 (0%)2/54 (3.7%)1/54 (1.9%)
Part 1 Cohort A9: Investigational COVID-19 Vaccine 10/52 (0%)1/52 (1.9%)6/52 (11.5%)
Part 1 Cohort A2: mRNA-1083.1 Dose Level 20/52 (0%)2/51 (3.9%)3/51 (5.9%)
Part 1 Cohort A3: mRNA-1083.1 Dose Level 30/33 (0%)0/33 (0%)2/33 (6.1%)
Part 1 Cohort A4: mRNA-1083.2 Dose Level 10/54 (0%)1/55 (1.8%)0/55 (0%)
Part 1 Cohort A5: mRNA-1083.2 Dose Level 20/54 (0%)1/53 (1.9%)6/53 (11.3%)
Part 1 Cohort A6: mRNA-1083.2 Dose Level 30/33 (0%)1/33 (3%)0/33 (0%)
Part 1 Cohort A7: mRNA-1083.30/53 (0%)1/53 (1.9%)0/53 (0%)
Part 1 Cohort B12: Influenza Vaccine 10/52 (0%)1/52 (1.9%)1/52 (1.9%)
Part 1 Cohort B11: Investigational Influenza Vaccine 20/56 (0%)2/55 (3.6%)3/55 (5.5%)
Part 1 Cohort B8: Investigational Influenza Vaccine 10/56 (0%)1/55 (1.8%)2/55 (3.6%)
Part 1 Cohort B10: COVID-19 Vaccine 10/56 (0%)0/53 (0%)2/53 (3.8%)
Part 1 Cohort B9: Investigational COVID-19 Vaccine 10/55 (0%)0/55 (0%)2/55 (3.6%)
Part 1 Cohort B1: mRNA-1083.1 Dose Level 10/56 (0%)1/56 (1.8%)7/56 (12.5%)
Part 1 Cohort B2: mRNA-1083.1 Dose Level 20/56 (0%)0/55 (0%)1/55 (1.8%)
Part 1 Cohort B3: mRNA-1083.1 Dose Level 30/37 (0%)1/37 (2.7%)2/37 (5.4%)
Part 1 Cohort B4: mRNA-1083.2 Dose Level 10/55 (0%)1/56 (1.8%)4/56 (7.1%)
Part 1 Cohort B5: mRNA-1083.2 Dose Level 20/56 (0%)0/54 (0%)8/54 (14.8%)
Part 1 Cohort B6: mRNA-1083.2 Dose Level 30/38 (0%)1/38 (2.6%)5/38 (13.2%)
Part 1 Cohort B7: mRNA-1083.30/56 (0%)2/54 (3.7%)2/54 (3.7%)
Part 2: Influenza Vaccine 10/41 (0%)1/40 (2.5%)2/40 (5%)
Part 2: Investigational Influenza Vaccine 1 Dose Level 10/40 (0%)1/39 (2.6%)0/39 (0%)
Part 2: Investigational Influenza Vaccine 1 Dose Level 20/40 (0%)1/40 (2.5%)2/40 (5%)
Part 2: COVID-19 Vaccine 20/42 (0%)0/42 (0%)0/42 (0%)
Part 2: Investigational COVID-19 Vaccine 20/40 (0%)0/40 (0%)3/40 (7.5%)
Part 2: mRNA-1083 Composition 1 Dose Level 10/40 (0%)1/40 (2.5%)3/40 (7.5%)
Part 2: mRNA-1083 Composition 1 Dose Level 20/42 (0%)0/42 (0%)1/42 (2.4%)
Part 2: mRNA-1083 Composition 1 Dose Level 30/42 (0%)1/41 (2.4%)5/41 (12.2%)
Part 2: mRNA-1083 Composition 1 Dose Level 40/41 (0%)0/41 (0%)1/41 (2.4%)
Part 2: mRNA-1083 Composition 2 Dose Level 10/40 (0%)0/40 (0%)5/40 (12.5%)
Part 2: mRNA-1083 Composition 2 Dose Level 20/40 (0%)0/40 (0%)2/40 (5%)
Part 2: mRNA-1083 Composition 2 Dose Level 30/40 (0%)1/40 (2.5%)4/40 (10%)
Part 2: mRNA-1083 Composition 2 Dose Level 40/42 (0%)0/42 (0%)2/42 (4.8%)
Most frequent serious events
Showing 10 of 48
Most frequent serious events
EventPart 1 Cohort A12: Influenza Vaccine 1Part 1 Cohort A13: Influenza Vaccine 2Part 1 Cohort A11: Investigational Influenza Vaccine 2Part 1 Cohort A8: Investigational Influenza Vaccine 1Part 1 Cohort A10: COVID-19 Vaccine 1Part 1 Cohort A9: Investigational COVID-19 Vaccine 1Part 1 Cohort A2: mRNA-1083.1 Dose Level 2Part 1 Cohort A3: mRNA-1083.1 Dose Level 3Part 1 Cohort A4: mRNA-1083.2 Dose Level 1Part 1 Cohort A5: mRNA-1083.2 Dose Level 2Part 1 Cohort A6: mRNA-1083.2 Dose Level 3Part 1 Cohort A7: mRNA-1083.3Part 1 Cohort B12: Influenza Vaccine 1Part 1 Cohort B11: Investigational Influenza Vaccine 2Part 1 Cohort B8: Investigational Influenza Vaccine 1Part 1 Cohort B10: COVID-19 Vaccine 1Part 1 Cohort B9: Investigational COVID-19 Vaccine 1Part 1 Cohort B1: mRNA-1083.1 Dose Level 1Part 1 Cohort B2: mRNA-1083.1 Dose Level 2Part 1 Cohort B3: mRNA-1083.1 Dose Level 3Part 1 Cohort B4: mRNA-1083.2 Dose Level 1Part 1 Cohort B5: mRNA-1083.2 Dose Level 2Part 1 Cohort B6: mRNA-1083.2 Dose Level 3Part 1 Cohort B7: mRNA-1083.3Part 2: Influenza Vaccine 1Part 2: Investigational Influenza Vaccine 1 Dose Level 1Part 2: Investigational Influenza Vaccine 1 Dose Level 2Part 2: COVID-19 Vaccine 2Part 2: Investigational COVID-19 Vaccine 2Part 2: mRNA-1083 Composition 1 Dose Level 1Part 2: mRNA-1083 Composition 1 Dose Level 2Part 2: mRNA-1083 Composition 1 Dose Level 3Part 2: mRNA-1083 Composition 1 Dose Level 4Part 2: mRNA-1083 Composition 2 Dose Level 1Part 2: mRNA-1083 Composition 2 Dose Level 2Part 2: mRNA-1083 Composition 2 Dose Level 3Part 2: mRNA-1083 Composition 2 Dose Level 4
Upper respiratory tract infectionInfections and infestations0/540/530/540/510/540/520/510/330/550/531/330/530/520/550/550/530/550/560/550/370/560/540/380/540/400/390/400/420/400/400/420/410/410/400/400/400/42
Renal pseudoaneurysmRenal and urinary disorders0/540/530/540/510/540/520/510/330/550/530/330/530/520/550/550/530/550/560/551/370/560/540/380/540/400/390/400/420/400/400/420/410/410/400/400/400/42
Intestinal obstructionGastrointestinal disorders0/540/530/540/510/540/520/510/330/550/530/330/530/520/550/550/530/550/560/550/370/560/541/380/540/400/390/400/420/400/400/420/410/410/400/400/400/42
SepsisInfections and infestations0/540/530/540/510/540/520/510/330/550/530/330/530/520/550/550/530/550/560/550/370/560/540/380/540/401/390/400/420/400/400/420/410/410/400/400/400/42
SeizureNervous system disorders0/540/530/540/510/540/520/510/330/550/530/330/530/520/551/550/530/550/560/550/370/560/540/380/540/401/390/400/420/401/400/420/410/410/400/400/400/42
Coeliac artery compression syndromeGastrointestinal disorders0/540/530/540/510/540/520/510/330/550/530/330/530/520/550/550/530/550/560/550/370/560/540/380/540/401/390/400/420/400/400/420/410/410/400/400/400/42
Road traffic accidentInjury, poisoning and procedural complications0/540/530/540/510/540/520/510/330/550/530/330/530/520/550/550/530/550/560/550/370/560/540/380/540/401/390/400/420/400/400/420/410/410/400/400/400/42
CellulitisInfections and infestations0/540/530/540/510/540/520/510/330/550/530/330/530/520/550/550/530/550/560/550/370/560/540/380/540/400/390/400/420/401/400/420/410/410/400/400/400/42
Bipolar II disorderPsychiatric disorders0/540/530/540/510/540/520/510/330/550/530/330/530/520/550/550/530/550/560/550/370/560/540/380/541/400/390/400/420/400/400/420/410/410/400/400/400/42
Major depressionPsychiatric disorders0/540/530/540/510/540/520/510/330/550/530/330/530/520/550/550/530/550/560/550/370/560/540/380/540/400/390/400/420/400/400/420/410/410/400/401/400/42
Most frequent other events
Most frequent other events
EventPart 1 Cohort A12: Influenza Vaccine 1Part 1 Cohort A13: Influenza Vaccine 2Part 1 Cohort A11: Investigational Influenza Vaccine 2Part 1 Cohort A8: Investigational Influenza Vaccine 1Part 1 Cohort A10: COVID-19 Vaccine 1Part 1 Cohort A9: Investigational COVID-19 Vaccine 1Part 1 Cohort A2: mRNA-1083.1 Dose Level 2Part 1 Cohort A3: mRNA-1083.1 Dose Level 3Part 1 Cohort A4: mRNA-1083.2 Dose Level 1Part 1 Cohort A5: mRNA-1083.2 Dose Level 2Part 1 Cohort A6: mRNA-1083.2 Dose Level 3Part 1 Cohort A7: mRNA-1083.3Part 1 Cohort B12: Influenza Vaccine 1Part 1 Cohort B11: Investigational Influenza Vaccine 2Part 1 Cohort B8: Investigational Influenza Vaccine 1Part 1 Cohort B10: COVID-19 Vaccine 1Part 1 Cohort B9: Investigational COVID-19 Vaccine 1Part 1 Cohort B1: mRNA-1083.1 Dose Level 1Part 1 Cohort B2: mRNA-1083.1 Dose Level 2Part 1 Cohort B3: mRNA-1083.1 Dose Level 3Part 1 Cohort B4: mRNA-1083.2 Dose Level 1Part 1 Cohort B5: mRNA-1083.2 Dose Level 2Part 1 Cohort B6: mRNA-1083.2 Dose Level 3Part 1 Cohort B7: mRNA-1083.3Part 2: Influenza Vaccine 1Part 2: Investigational Influenza Vaccine 1 Dose Level 1Part 2: Investigational Influenza Vaccine 1 Dose Level 2Part 2: COVID-19 Vaccine 2Part 2: Investigational COVID-19 Vaccine 2Part 2: mRNA-1083 Composition 1 Dose Level 1Part 2: mRNA-1083 Composition 1 Dose Level 2Part 2: mRNA-1083 Composition 1 Dose Level 3Part 2: mRNA-1083 Composition 1 Dose Level 4Part 2: mRNA-1083 Composition 2 Dose Level 1Part 2: mRNA-1083 Composition 2 Dose Level 2Part 2: mRNA-1083 Composition 2 Dose Level 3Part 2: mRNA-1083 Composition 2 Dose Level 4
Upper respiratory tract infectionInfections and infestations0/540/532/540/510/542/521/510/330/553/530/330/530/521/550/552/530/553/560/551/372/566/540/381/541/400/392/400/421/402/400/422/411/413/401/402/401/42
COVID-19Infections and infestations0/540/530/540/510/540/520/510/330/550/530/330/530/520/550/550/530/550/560/550/370/560/540/380/541/400/390/400/422/401/401/423/410/412/401/401/401/42
Urinary tract infectionInfections and infestations0/541/532/541/511/542/521/512/330/551/530/330/531/521/550/551/531/552/560/550/371/561/541/380/540/400/390/400/420/400/400/420/410/410/400/401/400/42
Rhinovirus infectionInfections and infestations1/542/530/541/510/543/521/510/330/553/530/330/530/521/552/550/531/552/561/552/370/561/542/381/540/400/390/400/420/400/400/420/410/410/400/400/400/42
PalpitationsCardiac disorders0/540/530/541/510/540/520/510/330/550/530/330/530/520/550/550/530/551/560/550/371/560/542/380/540/400/390/400/420/400/400/420/410/410/400/400/400/42

Baseline characteristics

The FAS included all randomized participants who received the study intervention. Participants were analyzed according to the group to which they were randomized.

Age, Categorical
Age, Categorical(Participants)Part 1 Cohort A12: Influenza Vaccine 1Part 1 Cohort A13: Influenza Vaccine 2Part 1 Cohort A11: Investigational Influenza Vaccine 2Part 1 Cohort A8: Investigational Influenza Vaccine 1Part 1 Cohort A10: COVID-19 Vaccine 1Part 1 Cohort A9: Investigational COVID-19 Vaccine 1Part 1 Cohort A2: mRNA-1083.1 Dose Level 2Part 1 Cohort A3: mRNA-1083.1 Dose Level 3Part 1 Cohort A4: mRNA-1083.2 Dose Level 1Part 1 Cohort A5: mRNA-1083.2 Dose Level 2Part 1 Cohort A6: mRNA-1083.2 Dose Level 3Part 1 Cohort A7: mRNA-1083.3Part 1 Cohort B12: Influenza Vaccine 1Part 1 Cohort B11: Investigational Influenza Vaccine 2Part 1 Cohort B8: Investigational Influenza Vaccine 1Part 1 Cohort B10: COVID-19 Vaccine 1Part 1 Cohort B9: Investigational COVID-19 Vaccine 1Part 1 Cohort B1: mRNA-1083.1 Dose Level 1Part 1 Cohort B2: mRNA-1083.1 Dose Level 2Part 1 Cohort B3: mRNA-1083.1 Dose Level 3Part 1 Cohort B4: mRNA-1083.2 Dose Level 1Part 1 Cohort B5: mRNA-1083.2 Dose Level 2Part 1 Cohort B6: mRNA-1083.2 Dose Level 3Part 1 Cohort B7: mRNA-1083.3Part 2: Influenza Vaccine 1Part 2: Investigational Influenza Vaccine 1 Dose Level 1Part 2: Investigational Influenza Vaccine 1 Dose Level 2Part 2: COVID-19 Vaccine 2Part 2: Investigational COVID-19 Vaccine 2Part 2: mRNA-1083 Composition 1 Dose Level 1Part 2: mRNA-1083 Composition 1 Dose Level 2Part 2: mRNA-1083 Composition 1 Dose Level 3Part 2: mRNA-1083 Composition 1 Dose Level 4Part 2: mRNA-1083 Composition 2 Dose Level 1Part 2: mRNA-1083 Composition 2 Dose Level 2Part 2: mRNA-1083 Composition 2 Dose Level 3Part 2: mRNA-1083 Composition 2 Dose Level 4Total
<=18 years00000000000000000000000000000000000000
Between 18 and 65 years000000000000525555535555563755553854403940424040424141404040421147
>=65 years5453545154525133545433530000000000000000000000000596
Sex: Female, Male
Sex: Female, Male(Participants)Part 1 Cohort A12: Influenza Vaccine 1Part 1 Cohort A13: Influenza Vaccine 2Part 1 Cohort A11: Investigational Influenza Vaccine 2Part 1 Cohort A8: Investigational Influenza Vaccine 1Part 1 Cohort A10: COVID-19 Vaccine 1Part 1 Cohort A9: Investigational COVID-19 Vaccine 1Part 1 Cohort A2: mRNA-1083.1 Dose Level 2Part 1 Cohort A3: mRNA-1083.1 Dose Level 3Part 1 Cohort A4: mRNA-1083.2 Dose Level 1Part 1 Cohort A5: mRNA-1083.2 Dose Level 2Part 1 Cohort A6: mRNA-1083.2 Dose Level 3Part 1 Cohort A7: mRNA-1083.3Part 1 Cohort B12: Influenza Vaccine 1Part 1 Cohort B11: Investigational Influenza Vaccine 2Part 1 Cohort B8: Investigational Influenza Vaccine 1Part 1 Cohort B10: COVID-19 Vaccine 1Part 1 Cohort B9: Investigational COVID-19 Vaccine 1Part 1 Cohort B1: mRNA-1083.1 Dose Level 1Part 1 Cohort B2: mRNA-1083.1 Dose Level 2Part 1 Cohort B3: mRNA-1083.1 Dose Level 3Part 1 Cohort B4: mRNA-1083.2 Dose Level 1Part 1 Cohort B5: mRNA-1083.2 Dose Level 2Part 1 Cohort B6: mRNA-1083.2 Dose Level 3Part 1 Cohort B7: mRNA-1083.3Part 2: Influenza Vaccine 1Part 2: Investigational Influenza Vaccine 1 Dose Level 1Part 2: Investigational Influenza Vaccine 1 Dose Level 2Part 2: COVID-19 Vaccine 2Part 2: Investigational COVID-19 Vaccine 2Part 2: mRNA-1083 Composition 1 Dose Level 1Part 2: mRNA-1083 Composition 1 Dose Level 2Part 2: mRNA-1083 Composition 1 Dose Level 3Part 2: mRNA-1083 Composition 1 Dose Level 4Part 2: mRNA-1083 Composition 2 Dose Level 1Part 2: mRNA-1083 Composition 2 Dose Level 2Part 2: mRNA-1083 Composition 2 Dose Level 3Part 2: mRNA-1083 Composition 2 Dose Level 4Total
Female32302929333027163030142832233129282831173331243023202418152221221823252223941
Male22232522212224172424192520322424272725202224142417191624251821192317151819802
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1 Cohort A12: Influenza Vaccine 1Part 1 Cohort A13: Influenza Vaccine 2Part 1 Cohort A11: Investigational Influenza Vaccine 2Part 1 Cohort A8: Investigational Influenza Vaccine 1Part 1 Cohort A10: COVID-19 Vaccine 1Part 1 Cohort A9: Investigational COVID-19 Vaccine 1Part 1 Cohort A2: mRNA-1083.1 Dose Level 2Part 1 Cohort A3: mRNA-1083.1 Dose Level 3Part 1 Cohort A4: mRNA-1083.2 Dose Level 1Part 1 Cohort A5: mRNA-1083.2 Dose Level 2Part 1 Cohort A6: mRNA-1083.2 Dose Level 3Part 1 Cohort A7: mRNA-1083.3Part 1 Cohort B12: Influenza Vaccine 1Part 1 Cohort B11: Investigational Influenza Vaccine 2Part 1 Cohort B8: Investigational Influenza Vaccine 1Part 1 Cohort B10: COVID-19 Vaccine 1Part 1 Cohort B9: Investigational COVID-19 Vaccine 1Part 1 Cohort B1: mRNA-1083.1 Dose Level 1Part 1 Cohort B2: mRNA-1083.1 Dose Level 2Part 1 Cohort B3: mRNA-1083.1 Dose Level 3Part 1 Cohort B4: mRNA-1083.2 Dose Level 1Part 1 Cohort B5: mRNA-1083.2 Dose Level 2Part 1 Cohort B6: mRNA-1083.2 Dose Level 3Part 1 Cohort B7: mRNA-1083.3Part 2: Influenza Vaccine 1Part 2: Investigational Influenza Vaccine 1 Dose Level 1Part 2: Investigational Influenza Vaccine 1 Dose Level 2Part 2: COVID-19 Vaccine 2Part 2: Investigational COVID-19 Vaccine 2Part 2: mRNA-1083 Composition 1 Dose Level 1Part 2: mRNA-1083 Composition 1 Dose Level 2Part 2: mRNA-1083 Composition 1 Dose Level 3Part 2: mRNA-1083 Composition 1 Dose Level 4Part 2: mRNA-1083 Composition 2 Dose Level 1Part 2: mRNA-1083 Composition 2 Dose Level 2Part 2: mRNA-1083 Composition 2 Dose Level 3Part 2: mRNA-1083 Composition 2 Dose Level 4Total
Hispanic or Latino4463468454388287475597557342841011251066209
Not Hispanic or Latino504947475044432849493045445147465147503246483348333536403235322938343034351517
Unknown or Not Reported001102010100020001100001010001011100117
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1 Cohort A12: Influenza Vaccine 1Part 1 Cohort A13: Influenza Vaccine 2Part 1 Cohort A11: Investigational Influenza Vaccine 2Part 1 Cohort A8: Investigational Influenza Vaccine 1Part 1 Cohort A10: COVID-19 Vaccine 1Part 1 Cohort A9: Investigational COVID-19 Vaccine 1Part 1 Cohort A2: mRNA-1083.1 Dose Level 2Part 1 Cohort A3: mRNA-1083.1 Dose Level 3Part 1 Cohort A4: mRNA-1083.2 Dose Level 1Part 1 Cohort A5: mRNA-1083.2 Dose Level 2Part 1 Cohort A6: mRNA-1083.2 Dose Level 3Part 1 Cohort A7: mRNA-1083.3Part 1 Cohort B12: Influenza Vaccine 1Part 1 Cohort B11: Investigational Influenza Vaccine 2Part 1 Cohort B8: Investigational Influenza Vaccine 1Part 1 Cohort B10: COVID-19 Vaccine 1Part 1 Cohort B9: Investigational COVID-19 Vaccine 1Part 1 Cohort B1: mRNA-1083.1 Dose Level 1Part 1 Cohort B2: mRNA-1083.1 Dose Level 2Part 1 Cohort B3: mRNA-1083.1 Dose Level 3Part 1 Cohort B4: mRNA-1083.2 Dose Level 1Part 1 Cohort B5: mRNA-1083.2 Dose Level 2Part 1 Cohort B6: mRNA-1083.2 Dose Level 3Part 1 Cohort B7: mRNA-1083.3Part 2: Influenza Vaccine 1Part 2: Investigational Influenza Vaccine 1 Dose Level 1Part 2: Investigational Influenza Vaccine 1 Dose Level 2Part 2: COVID-19 Vaccine 2Part 2: Investigational COVID-19 Vaccine 2Part 2: mRNA-1083 Composition 1 Dose Level 1Part 2: mRNA-1083 Composition 1 Dose Level 2Part 2: mRNA-1083 Composition 1 Dose Level 3Part 2: mRNA-1083 Composition 1 Dose Level 4Part 2: mRNA-1083 Composition 2 Dose Level 1Part 2: mRNA-1083 Composition 2 Dose Level 2Part 2: mRNA-1083 Composition 2 Dose Level 3Part 2: mRNA-1083 Composition 2 Dose Level 4Total
Race — White484746444443462845502745383943363736373041392237292625262529262424222222291277
Race — Black or African American65869755546613127141211163111114147712107610109137139330
Race — Asian010111002000124234230412463543456373390
Race — American Indian or Alaska Native00000000100001001000001000000000000004
Race — Native Hawaiian or Other Pacific Islander00000000000000000200100000010010000005
Race — Multiracial000000001000000021010001000011111111014
Race — Other000000000002001101101100000011001030014
Race — Unknown00000000000001000000000000000000000001
Race — Not Reported00000100000000000000100000002001010118
08

Study locations

69 sites
  • Chandler Clinical Trials
    Chandler, Arizona 85224-6231, United States
  • Benchmark Research
    Colton, California 92324, United States
  • Marvel Clinical Research
    Huntington Beach, California 92647-6835, United States
  • Central Valley Research
    Modesto, California 95350-5365, United States
  • Benchmark Research
    Sacramento, California 95864-3102, United States
  • Tekton Research
    Longmont, Colorado 80501-6461, United States
  • Accel Research Sites
    DeLand, Florida 32720-0834, United States
  • CenExel
    Hollywood, Florida 33024, United States
  • Nature Coast Clinical Research
    Inverness, Florida 34452, United States
  • Jacksonville Center For Clinical Research
    Jacksonville, Florida 32216, United States
  • Accel Research Sites
    Maitland, Florida 32751, United States
  • Suncoast Research Group
    Miami, Florida 33135-1687, United States
  • Centricity Research
    Columbus, Georgia 31904, United States
  • Accel Research Site
    Decatur, Georgia 30030-2615, United States
  • CenExel iResearch
    Decatur, Georgia 30030, United States
  • Lifeline Primary Care
    Lilburn, Georgia 30047-2832, United States
  • Koch Family Medicine
    Morton, Illinois 61550, United States
  • Optimal Research
    Peoria, Illinois 61614-4885, United States
  • DM Clinical Research
    River Forest, Illinois 60305-1876, United States
  • Johnson County Clin-Trials
    Lenexa, Kansas 66219-1389, United States
  • Tekton Research
    Wichita, Kansas 67218-2913, United States
  • Versailles Family Medicine
    Versailles, Kentucky 40383-1947, United States
  • Velocity Clinical research
    Baton Rouge, Louisiana 70809, United States
  • Benchmark Research
    Metairie, Louisiana 70006, United States
  • DelRicht Research
    New Orleans, Louisiana 70115, United States
  • DelRicht Research
    Prairieville, Louisiana 70769, United States
  • Annapolis Internal Medicine
    Annapolis, Maryland 21401, United States
  • Velocity Clinical Research
    Rockville, Maryland 20854, United States
  • DM Clinical Research
    Brookline, Massachusetts 02445-7113, United States
  • Vida Clinical Studies
    Dearborn Heights, Michigan 48127-2234, United States
  • DelRicht Research
    Gulfport, Mississippi 39503, United States
  • Clay Platte Family Medicine
    Kansas City, Missouri 64151-2411, United States
  • Velocity Clinical Research
    Lincoln, Nebraska 68510, United States
  • Velocity Clinical Research
    Norfolk, Nebraska 68701, United States
  • Excel Clinical Research
    Las Vegas, Nevada 89109-6209, United States
  • CCT Research
    Las Vegas, Nevada 89119, United States
  • Las Vegas Clinical Trials
    North Las Vegas, Nevada 89030-7193, United States
  • Rochester Clinical Research
    Rochester, New York 14609-3169, United States
  • Tryon Medical Partners
    Charlotte, North Carolina 28210, United States
  • Trial Management Associates
    Wilmington, North Carolina 28403-6238, United States
  • CTI Clinical Research Center
    Cincinnati, Ohio 45212, United States
  • Velocity Clinical Research
    Cincinnati, Ohio 45219, United States
  • Velocity Clinical Research
    Cincinnati, Ohio 45246, United States
  • Centricity Research
    Columbus, Ohio 43213, United States
  • WellNow Urgent Care & Research
    Dayton, Ohio 45424-4019, United States
  • Lynn Institute of East Oklahoma
    Oklahoma City, Oklahoma 73111-3324, United States
  • DelRicht Research
    Tulsa, Oklahoma 74133, United States
  • Tekton Research Inc
    Yukon, Oklahoma 73099-9518, United States
  • DM Clinical Research
    Philadelphia, Pennsylvania 19107-1530, United States
  • Mercado Medical Practice
    Philadelphia, Pennsylvania 19111-2432, United States
  • DelRicht Research
    Charleston, South Carolina 29407, United States
  • Trial Management Associates
    Myrtle Beach, South Carolina 29572-4612, United States
  • Medical Care
    Elizabethton, Tennessee 37643, United States
  • DelRicht Research
    Hendersonville, Tennessee 37075, United States
  • Benchmark Research
    Austin, Texas 78705-3298, United States
  • Tekton Research
    Austin, Texas 78745-1470, United States
  • Tekton Research
    Beaumont, Texas 77706-3061, United States
  • Benchmark Research
    Fort Worth, Texas 76135, United States
  • Cyfair Clinical Research
    Houston, Texas 77065, United States
  • Texas Center for Drug Development
    Houston, Texas 77081, United States
  • DelRicht Research
    McKinney, Texas 75070, United States
  • Benchmark Research
    San Angelo, Texas 76904-7610, United States
  • Tekton Research
    San Antonio, Texas 78229, United States
  • CCT Research
    Pleasant View, Utah 84404, United States
  • Ogden Clinic
    Roy, Utah 84067, United States
  • JBR Clinical Research
    Salt Lake City, Utah 84107, United States
  • Meridian Clinical Research
    Hampton, Virginia 23666, United States
  • Velocity Clinical Research
    Portsmouth, Virginia 23703, United States
  • Wenatchee Valley Hospital & Clinics Campus
    Wenatchee, Washington 98801, United States
09

References and documents

Publications

  • Rudman Spergel AK, Ananworanich J, Guo R, Deng W, Carmona L, Schaefers K, Paila YD, Kandinov B, Eger CH, Sinkiewicz M, Shao S, Henry C, Shaw CA. mRNA-based seasonal influenza and SARS-CoV-2 multicomponent vaccine in healthy adults: a phase 1/2 trial. Nat Med. 2025 May;31(5):1484-1493. doi: 10.1038/s41591-025-03591-0. Epub 2025 Mar 18. PubMed 40102593 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Dec 2024, 19 months.

Results were first posted in Dec 2025, 1 year after primary completion.

Of 41 industry-sponsored phase 1/2 interventional studies under Influenza, Human, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's 19 months is above that.

Counting every sponsor, half of 43 studies reached it within 12 months; a quarter within 7 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2023
First posted
Apr 25, 2023
StartActual
Apr 14, 2023
Primary completionActual
Dec 3, 2024
CompletionActual
Dec 3, 2024
Results first posted
Dec 23, 2025
Last update
Dec 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05827926
Lead sponsor
ModernaTX, Inc.
Responsible party
Sponsor
First posted
Apr 25, 2023
Start date
Apr 14, 2023
Primary completion
Dec 3, 2024
Completion
Dec 3, 2024
Results posted
Dec 23, 2025
Last update
Dec 23, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MRNA-1083

Start the discussion